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1 ABSTRACT 
LINYI WEI: Design, Synthesis and Biological Evaluation of New Tylophorine 
Analogs as Potential Antitumor Agents 
(Under the direction of Kenan Professor Kuo-Hsiung Lee) 
 
 
Tylophorine and related phenanthroindolizidine alkaloids isolated principally from 
Asclepiadaceae have been targets of synthetic modification because of their profound 
cytotoxic antitumor activity.  As part of our interest in plant-derived antitumor agents, novel 
water-soluble phenanthrene-based tylophorine derivatives (PBTs) were designed, synthesized 
and evaluated for anticancer activity. 
Several PBTs showed superior activity profiles with EC50 values in the sub-micromolar 
range, which are comparable to those of currently used antitumor drugs.  A structure-activity 
relationship (SAR) study was also explored to facilitate the further development of this new 
compound class.  
Subsequently, C9-substituted PBTs were designed and synthesized using 2, 3 
methylenedioxy-6-methoxyphenanthrene as a common skeleton based on our prior SAR 
findings. The C-9 site is an ideal position for introducing more polar, water-solubility-
enhancing moieties.  We also extended the in vitro antitumor screening to include additional 
significant tumor types [A549 (lung), DU-145 (prostate), ZR-751 (breast), KB 
(nasopharyngeal)] as well as a multi-drug resistant cancer cell subline [KB-Vin (multi-drug 
 iii
resistant KB subline)]. Most of the compounds showed fairly uniform and potent cytotoxic 
activity with EC50 ≅10-7 M against both wild type and matched multi-drug resistant KB cell 
lines, and displayed notable selectivity toward DU-145 (prostate) and ZR-751 (breast) cancer 
cell lines.  
A combination of QSAR modeling and database mining was used to facilitate further 
design and discovery of novel anticancer PBTs.  MolConnZ 2D topological descriptors were 
applied to a dataset of 52 chemically diverse PBTs and variable selection models were 
generated using the κ nearest neighbor (κNN) method.  The derived κNN QSAR models 
have high internal accuracy, with leave-one-out cross-validated R2 (q2) values ranging 
between 0.6 and 0.8.  The original dataset was then divided into several training and test sets 
to provide highly predictive models with q2 values greater than 0.5 for the training sets and 
R2 values greater than 0.6 for the test sets.  The ten best models were capable of mining the 
commercially available ChemDiv Database (450,000 compounds) and resulted in 34 
consensus hits.  Of these 34 compounds, 10 compounds were tested and 8 were confirmed to 
be active with a best EC50 of 1.8 µM.  These models were further validated by predicting the 
activity of four new PBTs compounds with reasonable accuracy and 11 consensuses hits with 
R2 of 0.52.  These results indicate that this approach can be successfully applied to further 
design and discovery of anticancer drug candidates from this compound class. 
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4  
1 CHAPTER I.  TYLOPHORINE AND ITS ANALOGS 
 
1.1 ISOLATION OF TYLOPHORA  
 
Figure 1-1. Tylophora (Asclepiadaceae) 
 
Tylophorine (1) (Figure 1-2) and its analogs, phenanthroindolizidine alkaloids also 
referred to as tylophora alkaloids, have been isolated primarily from plants of the family 
Asclepiadaceae1-4 (Figure 1-1), including members of the genus Tylophora, Vincetoxicum, 
Pergularia, Cynanchum, but also from Hypoestes verticillaris (Acanthaceae),5 Cryptocarya 
phyllostemmon (Lauraceae),6 Ficus hispida,7 and F. septica (Moraceae).8  The most 
important phenanthroindolizidine alkaloids are tylophorine (1), tylocrebrine (2), antofine (3) 
and tylophorinine (4) (Figure 1-2).  
 
OMe
MeO
MeO
R2
R1 N
H
1. Tylophorine: R1=H, R2= OMe
2. Tylocrebrine: R1=OMe, R2= H
3. Antofine:  R1=H, R2= H
MeO
MeO
OMe
N
H
OH
4. Tylophorinine
 
Figure 1-2. Chemical structures of tylophorine, tylocrebrine, antofine, and tylophorinine. 
 
1.2 CHEMICAL SPECTRUM OF TYLOPHORA 
A
B
C
D
E
N
O
O O
C6H6
 
 
   Figure 1-3. Tylophorine B benzene solvate. 
 
Pure dried tylophorine is a yellow powder and crystallization in common solvents is 
difficult.  Tylophorine B’s (Figure 1-3) structure has conjoined phenanthrene and 
indolizidine moieties.  The aromatic rings lie almost in the same plane with dihedral angles 
of 1.7o (A/B), 2.8o (B/C), 2.2o (A/C), and 7.3o (B/D).  The E ring adopts an envelope 
conformation and makes a dihedral angle of 6.7(3)° with the D ring.9  
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1.3 TOTAL SYNTHESIS OF TYLOPHORINE-RELATED ALKALOIDS 
The tylophorine (phenanthroindolizidine alkaloid) nucleus was first synthesized by 
Govindachari et al. in 195810 followed by the synthesis of cryptopleurine 
(phenanthroquinolizidine alkaloid) by Bradsher and Berger11 as well as Marchini and 
Belleau.12  Most naturally occurring tylophorine alkaloids (e.g., tylophorine, tylophorinine, 
and tylocrebine) have been synthesized, and the earlier routes before 1985 were well 
summarized in a comprehensive review by Suffness and Cordell.13  The more recently 
reported synthetic approaches have been reviewed by Li et al.14and Michael.15,16
1.4 SAR OF TYLOPHORINE-RELATED ALKALOIDS 
N
Me
O
MeO
O
Me
MeO
 
Figure 1-4. Triangulation of N-O-O in nonalkylating antileukemic agents. 
 
 
In 1970, Zee-Cheng and Cheng17 proposed a common structural feature among non-
alkylating antileukemic agents, including emetine, camptothecin, tylocrebrine, tylophorine, 
vinblastine, and vincristine.  This commonality involves a triangulation composed of one 
nitrogen and two oxygen atoms with relatively definite interatomic distances (Figure 1-4).   
N N
 
 3
Figure 1-5. A model for the binding of emetine-type agonist to the hypothetical receptor 
site. 
 
An extensive structure-activity by Gupta et al.18, 19 regarding cross-resistance in two 
emetine-resistant CHO cell variants showed that phenanthroindolizidine alkaloids, 
phenanthroquinolizidines, and the emetine-related benzoquinolizidines may have the same 
site of action.  The conformation of emetine was suggested to have a close spatial 
relationship to the other three compounds classes, and thus, they could bind to the same 
hypothetical binding site (Figure 1-5).  Alkaloids that did not fit into this spatial hypothesis, 
including benzylisoquinilines and protoberberines, were not resistant to emetine-resistant cell 
lines.  Therefore, the authors suggested that phenanthroindolizidine alkaloids, 
phenanthroquinolizidines, and emetine-related benzoquinolizidines possess common 
structural determinants responsible for their protein synthesis inhibitory activity.  Similar 
results have been reported from studies on yeast.20 Based on structural-activity comparisons, 
the required features are a planar molecule with two aromatic rings rendered slightly 
electronegative by methoxy or hydroxy groups and a free electron pair on nitrogen at a 
central distance from the aromatic rings. 
Staerk et al.21 assessed the cytotoxic activity of seven phenanthroindolizidine alkaloids, 
(-)-(R)-13aα-antofine (5), (-)-(R)-13aα-6-O-desmethylantofine (6), (-)-(R)-13aα-
secoantofine (7), (-)-(R)-13aα-6-O-desmethylsecoantofine (8), (-)-(R)-13aα-tylophorine (9), 
(-)-(R)-13aα-7-O-desmethyltylophorine (10), and (+)-(S)-13aβ-isotylocrebrine (11) (Figure 
1-6) against drug sensitive KB-3-1 and multidrug-resistant KB-V1 cancer cell lines.  
Compounds 7 and 8 showed remarkably decreased cytotoxicity compared with the five 
remaining compounds, suggesting that a rigid phenanthrene structure is a prerequisite for 
high cytotoxicity.  In addition, compounds belonging to the 13aR series and having a free 
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phenolic function at C-6 or C-7 showed greater cytotoxic activity against the KB cancer cell 
lines.  Although the S-configured 11 was less cytotoxic than the R series in this study, it still 
had quite high cytotoxicity against both cell lines (IC50=50 nM).  In contrast, previous studies 
showed equal or higher cytotoxicity with the 13aS series.22  
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11.
 
Figure 1-6. Chemical structures of phenanthroindolizidine alkaloids  
 
 
Moreover, by using secophenanthroindolizidine septicine (12) as a template, a novel 
series of 6,7-diphenylindolizidinones (Figure 1-7) was synthesized and tested for in vitro 
anticancer activity against various human cancer cell lines.23  Compounds with R = 3,4-
difluoro, 3,4-dimethoxy, 4-methyl, 4-fluoro, 4-trifluoromethyl, and 4-methylthio (13) showed 
significant potency with GI50 values in the range 2.1–8.1 µM.  However, the reduced 
compound 14 and septicine (12) were inactive in this assay; thus, proving the importance of 
the lactam carbonyl in the central indolizidine ring to the cytotoxic activity.  Substantial 
growth inhibitory activity was found when the 4-methylthio substituent was present in ring A, 
but substituents in ring B were less critical. Among all analogs, two compounds (R = 3, 4-
dimethoxy and 4-methyl) exhibited encouraging pharmacokinetic properties in mice.  
However, further evaluation of in vivo efficacy in a modified hollow fiber assay (HFA) was 
disappointing, probably due to poor solubility.  
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Figure 1-7. Structures of 6, 7-diphenylindolizidinones analogs. 
 
1.5 ANTITUMOR ACTIVITY OF TYLOPHORA  
Much of the current work on tylophorine alkloids was prompted by their profound 
antitumor activity.  Evaluation of tylophorine (1) and its analogs in the National Cancer 
Institute’s antitumor screen showed a uniform and potent growth inhibitory effect (GI50 ≅ 10-8 
M) against all 60 cell lines, with notable selectivity toward several refractory cell lines, 
including melanoma and lung tumor cell lines.24
In 1964, Gellert and Rudzats25 reported that administration of tylocrebrine (2), a 
phenanthrene alkaloid and positional isomer of tylophorine, caused approximately 50% 
increase in life span (ILS) in L1210 leukemia-bearing mice.  Similarly to 2, tylophorine (1) 
was active against L1210 leukemia but with lower efficacy (ILS ca. 30%).  Based on the 
novel structure and superior antitumor activity against L1210 leukemia, tylocrebrine was 
selected as a drug candidate and successfully proceeded to Phase I clinical trials in the early 
1960s.  However, the trials were eventually terminated in 1966 due to central nervous system 
(CNS) toxicity, primarily ataxia and disorientation.  Too few patients were treated to 
establish the efficacy of tylocrebrine. 
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1.6 MECHANISM OF ANTITUMOR ACTIVITY 
A comprehensive evaluation of tylophorine’s antitumor activities has not been reported, 
and its inhibition mechanisms on cell growth are largely unknown.  However, significant 
advances in the field of molecular biology over the past decade have led to a new era in 
cancer therapeutics and should facilitate our understanding of the mode of actions (MOA) of 
this compound class. 
1.6.1 Inhibition of DNA, RNA and Protein Synthesis 
Early mechanistic studies in the 1960s demonstrated that tylophorine alkaloids 
irreversibly inhibit DNA synthesis and protein synthesis at the elongation stage of the 
translation cycle.26 In HeLa cells, tylophorine reversibly inhibits RNA synthesis and 
irreversibly inhibits DNA synthesis, but its predominant effect is exerted on protein synthesis 
and elongation of peptide chains by preventing breakdown of polyribosomes and release of 
nascent peptides.  Tylophorine and tylocrebrine were also found to inhibit protein synthesis 
in Ehrlich ascites cells and yeast cytoplasmic ribosomes but had no effect on Escherichia coli 
(E. coli) ribosomes even at high concentrations.27   
Tylophorine, tylocrebrine, and cryptopleurine inhibit protein synthesis in eukaryotic 
cells.  Cryptopleurine at low concentration blocks translocation of peptidyl tRNA from the 
40S ribosomal A site to the P site, dependent on elongation factor EF-2 and GTP,28-30 and 
inhibits peptide bond formation in the 60S ribosomal unit at higher concentration.  In 
addition, tylophorine, tylocrebrine, tubulosine, and emetine compete with [14a-3H] 
cryptopleurine for a binding site on 80-, 60-, and 40-S ribosomal units and also inhibit the 
peptide-bond formation at high concentrations, implying that these compounds have a similar 
mechanism of action on protein synthesis inhibition.31
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1.6.2 Apoptosis Induction 
Ganguly et al.32 demonstrated that unspecified tylophora alkaloids could induce 
apoptosis in a human erythroleukemic cell line (K562) with characteristic apoptotic features, 
such as nuclear condensation apoptotic body formation, flipping of membrane 
phosphatidylserine, activation of caspase 3 and release of mitochondrial cytochrome c.  
These findings suggest that tylophora alkaloids, in addition to their antiproliferative activity, 
also induce apoptosis in tumor cells.  
1.6.3 Inhibition of Thymidylate Synthase (TS) and Dihydrofolate Reductase (DHFR) 
In the 1990s, it was found that tylophorine alkaloids target several key targets for cancer 
chemotherapy, including the metabolic enzymes thymidylate synthase (TS) and dihydrofolate 
reductase.33  TS catalyzes the reductive methylation of the substrate dUMP (2’-deoxyuridine 
5’-monophosphate) to dTMP (2’-deoxythymidine 5’-monophosphate; thymidylate) with 
concomitant conversion of the cofactor CH2THF (5,10-methylenetetra-hydrofolate) to DHF 
(7,8-dihydrofolate) (see Equation 1).   
 
dUMP + CH2THF → dTMP + DHF   Equation 1 
 
Thymidylate synthase (TS) and dihydrofolate reductase (DHFR) play a pivotal role in 
the provision of precursors (thymidylate) for DNA biosynthesis through a de novo pathway.  
In vitro studies of thymidylate synthase inhibition in human leukemic leukocytes showed that 
pergularinine (PGL) and tylophorinidine (TPD) from the Indian medicinal plant Pergularia 
pallida potently inhibited both chronic myelocytic leukemia (CML) and acute lymphocytic 
leukemia (ALL) (IC50 = 50 µM).  The authors indicated that 2 mol of PGL and TPD each 
bound irreversibly and covalently to one mole of L. leichmannii TS (Narasimha Rao et al., 
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unpublished data).  In contrast, binding to DHFR was slow and reversible.  Inhibition 
kinetics showed that the Ki values for PGL and TDP were 9 × 10-6 and 7 × 10-6 M, 
respectively.33 TS is highly elevated in human leukemia and it is also a good tumor marker to 
predict the progression of malignancy in leukemia and solid tumors such as breast and lung 
cancers.  Understanding of cancer biochemistry thus provides a good viewpoint for the 
design of enzyme targeted anticancer chemotherapy with this compound class. 
1.6.4 Inhibition of Activator Protein-1, CRE, and NF-kB 
Activator protein-1, CRE, and NF-κB signaling pathways have been well studied and are 
important players in the control of cell growth, differentiation, and survival.34-36  Gao et al.37 
found that NSC-717335, a stereoisomer of tylophorine, significantly inhibits activator 
protein-1, CRE, and nuclear factor κB (NF-κB) mediated transcription.  NSC-717335 and 
NSC-716802 had significant inhibitory effects on NF-κB mediated transcription with IC50 
values of 30 nM and 100 nM, respectively.  This result implied that tylophorine analogs may 
alter the activity of the above transcription factors, subsequently modulating the expression 
of their target genes involved in the control of cell growth, differentiation, and survival. 
In addition, Gao et al demonstrated that tylophorine analogs are active against HepG2 
tumor cells both in vitro and in vivo (HCC is refractory to chemotherapy because of tumor 
heterogeneity, the development of multidrug resistance phenotypes, and recently reported 
constitutive expression of NF-κB38).  One of the major problems with current cancer 
chemotherapy is drug resistance.  Recently, NF-kB has been suggested as one mechanism of 
drug resistance, because of its antiapoptotic role.39,40  Tumors that have constitutive NF-kB 
activity usually show increased resistance to chemotherapy.41  Another explanation might be 
that NF-kB is involved in regulation of p-glycoprotein, overexpression, which is a well 
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known mechanism of multidrug resistance to chemotherapy.  Consistent with Gao’s studies, 
Staerk et al.21 also showed that phenanthroindolizidine alkaloids were cytotoxic to both drug 
sensitive KB-3-1 and multidrug-resistant KB-Vin-1 cell lines, with low IC50 values 
comparable to those of modern cytostatic drugs.  This profile contrasts with those of many 
front-line antitumor drugs such as Catharanthus alkaloids and taxol, which are prone to 
multidrug-resistance based on glycoprotein transporter (MDR1) expressed in KB-Vin-1 cells.  
1.6.5 Selective Interaction between Tylophorine B and Bulged DNA  
Xi et al.42 studied the interaction between tylophorine B and bulged DNA using 
fluorescence spectroscopy and thermal melting methods.  Fluorescence quenched upon 
addition of the DNA, and the fluorescence intensity of tylophorine B tended to be constant at 
a high concentration of DNA, which suggests that the binding reaches saturation.  The 
binding stoichiometry of the tylophorine B-DNA complex is ca. 1:1.  The results indicate that 
oligonucleotides interact with tylophorine B at a submicromolar concentration, and the 
affinity for DNA bulge is optimal with Kd of 0.018 µM.  In addition, as a planar molecule as 
mentioned previously, tylophorine interacts with DNA through an intercalative association in 
which a planar, heteroaromatic moiety slides between the DNA A-T and T-A base pairs. 
1.7 CONCLUSION 
Over the years, natural products have contributed enormously to the treatment of various 
human diseases.  Recent findings demonstrate that tylophorines are cytotoxic to both drug 
sensitive and multidrug resistant cancer cells with a unique mode of action different from 
those of current known anticancer drugs.  Therefore, although the phenanthroindolizidine 
alkaloid tylocrebrine previously failed in clinical trials due to CNS toxicity, tylophorine has a 
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high potential to be developed into a new anticancer drug class, based on the profound 
cytotoxicity of these alkaloids, particularly to multidrug resistant cancer cells, and 
emphasized by recent findings of tylophorine’s mode of action in biological systems.
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2 CHAPTER II.  RESEARCH DESIGN 
 
2.1 INTRODUCTION 
Cancer is a group of more than 100 different diseases, characterized by uncontrolled 
cellular growth, local tissue invasion, and distant metastases.  Cancer claims approximately 
560,000 lives in the United States each year.  It is second only to cardiovascular disease as a 
cause of mortality.  The clinical use of chemotherapeutic agents against malignant tumors is 
successful in many cases but suffers from major drawbacks.  One drawback is lack of 
selectivity, which leads to severe systemic side effects and limited efficacy.  Another major 
problem is the emergence / selection of drug-resistance.   
Natural products have been the major source of currently available anticancer drugs.  
According to a review of New Chemical Entities (NCE) from 1981 to 2002,1 approximately 
74% of anticancer drugs were either natural products, natural product-based, or mimicked 
them in one form or another.  Therefore, as part of our studies in plant-derived antitumor 
agents, we have initiated the synthesis of new tylophorine (1) analogs.  Our design template 
is TSWUCC1 (Antofine) (2), a tylophorine analog isolated from Asclepiadaceae by Dr. K.H. 
Lee’s collaborator, Dr. T. S. Wu2 in Taiwan.  This compound showed both remarkable 
activity (EC50 10 ng/ml) and differential toxicity against different human cancer cell lines.  
The goal of this study is to generate and optimize phenanthrene derivatives as promising 
clinical trial candidates for treatment of cancer. 
 
2.2 SIGNIFICANCE 
Over the years, natural products have contributed enormously to the treatment of human 
diseases.  Recent findings have demonstrated that tylophorine alkaloids are cytotoxic to both 
drug sensitive and mutidrug resistant cell lines with unique mode(s) of action different from 
those of other known antitumor drugs.  These alkaloids possibly show an inhibitory effect on 
cyclic AMP response elements, activator protein-1 sites, or NF-κB binding site-mediated 
transcription, as well as potentiate retinoic acid differentiation to cause cancer cell apoptosis.  
Therefore, although the phenanthroindolizidine alkaloid tylocrebrine (3) previously failed in 
anticancer clinical trials due to CNS toxicity, this compound class merits further study in 
light of its profound cytotoxicity, particularly against multidrug resistant cancer cells.  A 
better understanding of mode(s) of action, formulation of structural-activity relationships in 
targeting specific tissue receptors, and synthesis of more polar analogs that are unable to pass 
the blood-brain barrier should help to generate optimal clinical trial candidates and develop 
this new class of anticancer drugs that may overcome the current issue of chemotherapy 
resistance.  [To date, bortezomib (4) (Figure 2-1), a proteasome inhibitor, is the only drug 
designed to target chemotherapy resistance by overcoming the anti-apoptosis mechanism of 
cancer cells through indirect inhibition of the NFκB pathway.] 
2.3 SPECIFIC AIMS 
Specific Aim 1:  
To design and synthesize novel phenanthrene alkaloid derivatives structurally related 
to tylophorine as a new class of potent antitumor agents. 
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TSWUCC1 (Antofine) (1) (Figure 2-1), a tylophorine analog isolated from Ficus septica 
by Dr. T. S. Wu in Taiwan, will be used as the template to design and synthesize new 
antitumor phenanthrene-based tylophorine (PBT) derivatives: 
1) Design and synthesis of phenanthroindolizidine alkaloid antofine. 
2) Design and synthesis of water soluble phenanthrene-based tylophorine derivatives 
(PBTs). 
3) Design and synthesis of 9-substituted PBTs. 
Specific Aim 2:  
To investigate the mode of action of this compound class.  
Compounds synthesized from specific aim 1 will be evaluated for their inhibitory effects 
on cancer cell growth, as well as in other biological assays both in-house (Dr. K.F. Bastow’s 
Laboratory, UNC) and at the National Cancer Institute (NCI), MD Anderson Cancer Center, 
as well as National Science and Techology Program for Bio- and Pharmaceuticals in Taiwan 
for in vivo activity.  All compounds will also be tested for anti-telomerase related antitumor 
activity in Dr. M. Jasfer’s laboratory, UNC.  The results from these biological assays will 
facilitate our understanding of the specific targets for this new compound class. 
Specific Aim 3:  
To generate QSAR models and use the resulting database for new lead identification. 
Based on the assumption that differences in structural properties account for differences 
in biological activities of compounds, validated predictive quantitative structure-activity 
relationship (QSAR) models will be generated using the chemical structures/activities of 
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compounds synthesized from Aim 1 and applied to database mining to assist further 
development of this new compound class. 
Specific Aim 4:  
To evaluate the pharmacokinetic profiles of phenanthrene derivatives and explore their 
potential for successful development into clinical trial candidates. 
An ADME prediction program will be used to evaluate the pharmacokinetic profile of 
the synthesized phenanthrene-based tylophorine (PBT) derivatives, including blood brain 
barrier (BBB) permeability, protein binding, and human intestinal absorption (HIA), for each 
promising analog in comparison to the parent tylophorine molecule. 
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Figure 2-1. Structures of tylophorine (1) TSWUCC1 (antofine) (2), tylocrebrine (3) and 
bortezomib (4). 
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3 CHAPTER III.  DESIGN, SYNTHESIS AND BIOLOGICAL 
EVALUATION OF NEW PHENANTHRENE-BASED 
TYLOPHORINE DERIVATIVES (PBTS) (PART I) 
 
 
3.1 INTRODUCTION 
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Figure 3-1. Structures of TSWUCC-1 (antofine) and tylocrebrine 
 
 
The total synthesis of TSWUCC-1 (Antofine 1) has been achieved by various groups.1-4  
We designed the following alternate synthetic route based on high reported yields for each 
step.  Initially, two commercially available appropriately substituted phenyl acetic acid (A) 
and o-nitrobenzaldehyde (B) compounds (Scheme 3-1) were condensed using a general 
Perkin condensation procedure.  After reduction of the nitro group to an amine, the key step 
in the synthesis involves formation of the phenanthrene unit by an improved, reported free-
radical Pschorr cyclization5 of the appropriately substituted stilbenic acid (D). The synthesis 
of this highly condensed pentacyclic natural product should be completed in three addition 
steps: amidation with proline methyl ester, carbonyl redution and a final polyphosphoric acid 
(PPA)-catalyzed ring closure.  However, the PPA catalyzed cyclisation (f) gave the unstable 
 
ketone intermediate H, which is very sensitive to moisture and acid, and resulted in extensive 
decomposition.  The relative low yield (10%) could not be improved by conventional 
Friedel-Crsfts acylation catalysis (acid chloride hydrochloride) or other dehydrogenation 
reagent, such as Eaton’s reagent, sulfuric acid and trifluoroacetic anhydride/acid.  The 
relative low yield of this ring closure halted the further development of this synthetic route to 
the natural product or its derivatives. 
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Scheme 3-1. Attempted total synthesis of TSWUCC1 
 
 
However, in a preliminary screen on all reaction intermediates, compound G, [N-(6-
benzyloxy-2,3-methylenedioxyphenanthr-9-ylmethyl)-L-proline] (Scheme 3-1), was 
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discovered serendipitously as a potent cytotoxic amino acid precursor of tylophorine.  It 
presents an unprecedented antitumor scaffold that led to our exploration of more polar 
(water-soluble) tylophorine-related derivatives.  Such phenanthrene-based tylophorine 
derivative or PBTs could circumvent this prior obstacle learned from the drug development 
failure of tylocrebrine (2) in the early 1960s due to its significant CNS toxicity, manifested as 
disorientation and ataxia.6  Increased polarity should diminish the CNS toxicity by 
preventing compounds from penetrating across the blood brain barrier.  Tylophorine 
alkaloids are composed of a phenanthrene ring system and an indolizidine moiety – and the 
rigid phenanthrene structure is a prerequisite for the antitumor activity.7 However, by 
opening the indolizidine ring, polar chemical moieties can easily be introduced into the 
compound skeleton.   
In addition, successful application of the Pschorr cyclization5 and coupling reaction in 
the presence of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) 
enabled efficient and concise access to these more polar and water soluble PBTs with overall 
yields greater than 50% (Scheme 3-1).  In comparison to the above reported total synthesis of 
tylophorine, our PBT synthesis avoids the cyclization step (limiting synthetic factor) and 
makes the parallel and large scale synthesis of PBTs feasible, which could potentially 
enhance the development of these compounds into drugs. 
Therefore, as part of our studies in plant-derived antitumor agents, this discovery led us 
to explore a new series of novel PBTs. We have initiated the design, synthesis and structure-
activity relationship (SAR) study of this new anticancer compound class.  The goal of this 
study is to generate and optimize PBTs as promising clinical trial candidates for treating 
cancer. 
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3.2 DESIGN OF SYNTHESIS 
Compound G was used as the template to design and synthesize PBT derivatives.  These 
compounds contain a core phenanthrene structure and can be synthesized efficiently in 
excellent yield as shown in Scheme3-2.  The newly synthesized PBTs were evaluated for 
cytotoxic activity against the A549 human cancer cell line and both structures and activities 
are listed in Tables 3-1, -2 and -3. 
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Scheme 3-2. Total synthesis of new phenanthrene-based tylophorine derivatives 
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3.3 CHEMISTRY   
Compounds 10-49 were synthesized following the efficient reported procedure5 outlined 
in Scheme 3-2.  A commercially available substituted O-nitrobenzaldehyde (3a,b) was 
treated with 4-methoxy or -benzyloxyphenyl acetic acid (4a,b) in the presence of Ac2O 
(Perkin condensation) to yield an intermediate nitro-substituted cinnamic acid (5a-c). The 
nitro group of 5 was converted to an amine using ammoniacal ferrous sulfate (FeSO4) to 
provide the amino-substituted cinnamic acid (6a-c).  Phenanthrenes 7a-c, which are the key 
intermediates in our method, were formed by an improved free-radical Pschorr cyclization5 in 
high yield.  Compound 6 was treated with sodium nitrite in 48% fluoroboric acid, and the 
resulting diazonium tetrafluoroborate was then efficiently cyclized to the phenanthrene-9-
carboxylic acid (7) using catalytic ferrocene.  Intermediates 7a-c were then condensed with 
the appropriate protected cyclic or acylic amino acid in the presence of N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC), 4-
(dimethylamino)pyridine (DMAP) and 1-hydroxybenzotriazole (HOBT) to give the amido-
substituted phenanthrene (8).  These mild conditions avoid the production of degradation 
products resulting from the acidic instability of the methylenedioxy group.  Selective 
reduction of the amide carbonyl group to a methylene was achieved by using borane-methyl 
sulfide complex (BMS, 2.0M solution in THF) to provide 9.  The C-9 side chain methyl ester 
was converted to carboxylic acid and hydroxymethyl groups by basic hydrolysis and lithium 
aluminum hydride reduction, respectively.  The 6-phenolic analogs were prepared by 
hydrogenolysis (H2, Pd/C) of the benzyloxy protecting group. 
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3.4 RESULTS AND DISCUSSION 
Tables 3-1 – 3-3 summarize the structures of newly synthesized PBTs (7a-c, 10–42) and 
their cytotoxic activity (EC50) against the A549 lung cancer cell line.  Etoposide (VP-16) was 
used as the reference compound. 
Structure-Activity Relationship (SAR) Analysis 
All three intermediate phenanthrene-9-carboxylic acids 7a-c were inactive.  Thus, the 
rigid, planar phenanthrene system is not sufficient for cytotoxic activity, and an appropriate 
C-9 side chain is crucial.  However, the phenanthrene system is required for cytotoxic 
activity, as the seco analogues 39-42, which contain an active proline side chain (see 
discussion below) but only a stilbene skeleton, were also inactive.  
Active analogs contained both cyclic (pyrrole/proline, piperidine/pipecolinic acid) and 
acylic (aminopentanoic, aminohexanoic acids) nitrogen-containing side chains at the C-9 
position of phenanthrene.  However, the linkage between the nitrogen and the phenanthrene 
was very critical.  Reduction of the amide carbonyl to methylene could dramatically increase 
the cytotoxic activity as shown in the comparison of 16 (L-proline amide, carbonyl linkage, 
EC50 42.6 µM) and 18 (methylene linkage, EC50 4.4 µM).  This observation (carbonyl, 
unfavorable or less favorable; methylene, favorable) also could be seen in comparison of 
11/12 and 25/27.  A simple explanation for this observation could possibly be the difference 
in configurational constraint.  The carbonyl is conjugated with the phenanthrene ring and, 
thus, extends the coplanarity, while the methylene substituent can rotate freely around the C-
C bond.  The former geometric restriction appears to disfavor cytotoxic activity and may 
prevent the molecule from attaining the optimal conformation for binding to an assumed 
biological target.  
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On the phenanthrene skeleton, changing the benzyloxy moiety at the C-6 position to a 
hydroxy group was extremely detrimental to activity (cf. 18/23 and 20/24).  In addition, 
active compounds with a 6-benzyloxy moiety (15 and 18-21, EC50 1.3 – 4.4 µM) were 
generally slightly less potent than corresponding analogs with a 6-methoxy group (27 and 31-
34, EC50 0.16 − 2.1 µM).  Thus, the rank order of potency at the phenanthrene C-6 position 
was methoxy > benzyloxy >> hydroxyl, suggesting that this position cannot tolerate the 
introduction of a polar moiety.  A hydrophilic moiety may be disfavored because a 
hydrophobic interaction occurs at this position between the compound and biological target 
that is essential for cytotoxic activity. 
Interestingly, active compounds with a 2,3-methylenedioxy group (33 and 34, EC50 0.5 
and 0.16 µM) were up to 40 times more potent than the corresponding compounds with a 
2,3-dimethoxy moiety (37 and 38, EC50 9.7 and 6.3 µM).  Thus, the five-membered 
methylenedioxy ring extension at the phenanthrene C2-C3 is quite favorable for cytotoxic 
activity.  
In the amino side chain, when the terminal carboxylic acid group was masked as the 
methyl ester, the cytotoxic activity was diminished drastically or abolished (e.g., 14/15, 
17/18, 26/27, 30/31).  However, reduction of the carboxylic acid to the hydroxymethyl 
generally increased activity, both in cyclic (18/19, 20/21, 31/32, 33/34, 37/38) and acylic 
(12/13, 27/28, 35/36) analogs.  Thus, the rank order of potency of the terminal polar 
substituent was hydroxy > carboxylic acid >> methyl ester.  
In summary, the favorable modification for these novel PBTs are as follows.  1) A planar 
phenanthrene system is required, but not sufficient for cytotoxic activity.  2) A N-hydrophilic 
substituent at the C-9 position is essential for the enhanced cytotoxicity and should be linked 
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through a methylene rather than a carbonyl group.  3) This C-9 N-hydrophilic substituent is 
ideal for the introduction of a polar moiety.  Analogs containing terminal carboxylic acid or 
hydroxymethyl groups are more favorable than those with methyl esters.  4) On the 
phenanthrene skeleton, a methoxy substituent best fits both the steric and electronic 
requirements at the C-6 position and is preferred over benzyloxy and hydroxy groups.  5) 
Adding a methylenedioxy ring at the 2,3 position of the planar phenanthrene system can 
dramatically enhance the cytotoxic activity and led to the most potent derivatives.  
3.5 CONCLUSION 
In this study, a total of 33 novel phenanthrene-based tylophorine derivatives (PBTs) 
were synthesized and evaluated for cytotoxic activity against human A549 lung cancer cells.  
Among these compounds, N-(2,3-methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-2-
piperidinemethanol (34) and N-(2,3-methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-5-
aminopentanol (28) were the most potent compounds designed and synthesized to date with 
EC50 values of 0.16 and 0.27 µM, respectively.  These two compounds incorporated all of the 
favorable modifications identified to date.  They possess a novel structure and showed 
remarkable EC50 values in the sub-micromolar range, comparable with front-line 
antineoplastic drugs such as etoposide, suggesting that this new compound class is worthy of 
further development as potential antitumor clinical trials candidates 
3.6 EXPERIMENTAL SECTION 
3.6.1 Instruments and Chemicals 
Melting points were measured using a Fisher Johns melting apparatus without correction.  
Proton nuclear magnetic resonance (1H NMR) spectra were measured on a 300 MHz Varian 
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Gemini 2000 spectrometer using TMS as internal standard.  The solvent used was CDCl3 
unless indicated.  Mass spectra were recorded on a PE-Sciex API-3000 LC/MS/MS 
instrument equipped with a Turbo IonsSpray ion source.  Elemental analyses were performed 
by Atlantic Microlab, Inc., Norcross, GA.  All active target compounds were analyzed for C, 
H, N and gave values within +0.4% of the theoretical values.  The purity of inactive target 
compounds was verified by HPLC using three different solvent systems  Thin-layer 
chromatography (TLC) was performed on PLC silica gel 60 F254 plates (0.5 mm, Merck). 
Biotage Flash+ and Isco Companion systems were used as medium-pressure column 
chromatography.  Silica gel (200-400 mesh) from Aldrich, Inc. was used for column 
chromatography.  4-Benzyloxyphenylacetic acid and 3, 4-methylenedioxy-6-
nitrobenzaldehyde were purchased from TCI.  L-Pipecolinic acid and isonipecotic acid were 
commercially available from Lancaster.  All other chemicals were obtained from Aldrich, Inc. 
and Fisher, Inc.  
3.6.2 General Preparation  
General procedure for the preparation of phenanthrene-9-carboxylic acids (a,b,c): 
Phenanthrene-9-carboxylic acids 7a and 7b were synthesized following a reported 
procedure.4
A solution of 3, 4-methylenedioxy-6-nitrobenzaldehyde (12 mmol), triethyl amine (12 
mmol), and 4-benzyloxy- or 4-methoxy-phenylacetic acid (17 mmol) was refluxed with 
stirring under Ar for 40 min. Water (30 ml) was added to the reaction mixture and the 
temperature was maintained between 90 °C and 100 °C during the addition. The reaction 
mixture was cooled to rt and the solid was collected by filtration and recrystallized from 
EtOH. 
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To a solution of the nitrocinnamic acid (7 mmol) in 10% aqueous NH4OH (100 ml) was 
added ferrous sulfate heptahydrate (15 g) dissolved in distilled water (100 mL) and 
concentrated aqueous NH4OH (100 mL). The reaction mixture was refluxed for 1.5 h, cooled 
to 40 °C, filtered through Celite, and acidified with HOAc (100 mL).  The resulting solid was 
collected by filtration and recrystallized from EtOH to yield the aminocinnamic acid. 
A solution composed of the aminocinnamic acid (3 mmol), NaOH (33 mmol) and 
NaNO2 in water (10 mL) was added dropwise over 30 min with stirring to 48% fluoroboric 
acid (43 mmol) at 0-5 °C. The mixture was stirred for 1 h, after which sulfamic acid was 
added until the mixture tested negative to starch-iodide paper. The crude solid was collected 
by filtration, dissolved in anhydrous acetone (10 mL) and then added dropwise with stirring 
over a 15 min period to ferrocene (0.056 g, 0.3 mmol) in acetone at rt. After an additional 15 
min of stirring, the green reaction mixture was added to water (100 mL). A light-yellow 
precipitate was collected and the trace amount of ferrocene was removed in vacuo to afford 
the phenanthrene-9-carboxylic acid. 
General procedure for the protection of cycloalkylamino acid: 
To a solution of cycloalkylamino acid (4 mmol) in dry MeOH (4 mL) was added 
dropwise SOCl2 (0.4 mL) at –30 °C. The reaction mixture was warmed to rt and refluxed for 
1 h. Then the solvent was removed in vacuo and the product was used in the next reaction 
without further purification. 
General procedure for the protection of acyclic alkylamino acid:
To a solution of dry MeOH (3 mL) was added dropwise acetyl chloride (0.45 mL) at 0 
°C. After 10 min stirring, the amino acid was added to the solution in portions. The mixture 
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was warmed to rt and refluxed for 2 h, then the solvent was removed in vacuo and the 
product was used in the next reaction without further purification. 
General procedure for the peptide bond condensation reaction (d): 
To a solution of phenanthrene-9-carboxylic acid (4 mmol), 4-(dimethylamino) pyridine 
(DMAP) (2 mmol), 1-hydroxybenzotriazole (HOBT) (4 mmol) in 20 mL DMF was added 
NMM (1.028 mL). After the mixture was stirred at 0 °C for 15 min, N-(3-
dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (EDC) (4.4 mmol) was added in 
portions, then methyl protected amino acid (4.4 mmol) was added after 30 min stirring. The 
reaction mixture was stirred overnight at rt and partitioned between EtOAc and water. The 
organic layer was washed with brine, saturated NaHCO3 and 1N HCl, dried over Na2SO4, 
and concentrated in vacuo. The crude product was chromatographed using Biotage Flash+ 
and Isco Companion systems using a 40g silica cartridge and EtOAc/hexane as eluant. 
General Procedure for the carbonyl reduction reaction (e): 
To a stirred solution of 9-amido-substituted phenanthrene (8 in Scheme 3-2, 2 mmol) in 
THF (20 mL) was added dropwise borane-methyl sulfide (BMS) (4 mL, 2.0M solution in 
THF). The reaction mixture was stirred at rt overnight and quenched with 1N HCL. THF was 
removed in vacuo, and the residue was partitioned between CH2Cl2 and water. The organic 
layer was dried, filtered, and evaporated to afford the target product (9 in Scheme 3-2). The 
crude product was chromatographed using Biotage Flash+ and Isco Companion systems 
using MeOH/CH2Cl2 as eluant. 
General Procedure for the catalytic cleavage (f):  
A solution of benzyoxy derivative (1mmol) and Pd/C (10%) was hydrogenated in a Parr 
apparatus (30 psi) for 2 h. The reaction mixture was filtrated through Celite, and filtrate was 
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concentrated in vacuo and was chromatographed using Biotage Flash+ and Isco Companion 
systems using MeOH/CH2Cl2 as eluant. 
General Procedure for the LiAlH4 reduction (g): 
To a suspension of methyl ester (1mmol) in 15 ml dry THF was added LiAlH4 (1g) in 
portions at 0 °C. After addition, the reaction mixture was refluxed for 4 h, and then cooled to 
0 °C. The reaction mixture was quenched with methnol, and then 10% Rochelle salt was 
added. The reaction mixture was extracted with water and 10% MeOH/CH2Cl2. The organic 
layer was dried over Na2SO4, and the crude product was chromatographed using Biotage 
Flash+ and Isco Companion systems using MeOH/CH2Cl2 as eluant. 
General Procedure for the basic hydrolysis reaction (h): 
A solution of ester in a 1:1 mixture of 4N NaOH and MeOH was refluxed for 4 h. The 
reaction mixture was acidified and partitioned between 10% MeOH/CH2Cl2 and 1N HCl. 
The organic layer was dried over Na2SO4, filtered, and evaporated. The crude product was 
chromatographed using Biotage Flash+ and Isco Companion systems using MeOH/CH2Cl2 
as eluant. 
3.6.3 Chemistry 
2,3-Methylenedioxy-6-benzyloxy-phenanthrene-9-carboxylic acid (7a) 
75% yield over two steps; mp 263-265 oC; 1H NMR (400.13 MHz) δ 8.40 (d, J=4Hz, 1H), 
7.92 (d, J=2Hz, 1H), 7.88 (s, 1H), 7.52 (m, 2H), 7.38 (m, 5H), 7.26 (dd, J=4Hz, 2Hz, 1H), 
6.14 (d, J= 4Hz, 2H), 5.35 (d, J=7Hz, 2H); MS (DCI/NH3) m/e: 373 (M + H)+.  
2,3-Methylenedioxy-6-methoxy-phenanthrene-9-carboxylic acid (7b) 
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78% yield; white powder; mp 293-295 oC; 1H NMR (400.13 MHz) δ 7.67 (s, 1H), 7.60 (d, J= 
4Hz, 1H), 7.22 (dd, J= 4Hz, 2Hz, 1H), 6.92 (s, 1H), 6.89 (d, J=2Hz, 1H), 6.70 (s, 1H), 5.98 
(s, 2H), 3.79 (s,3H); MS (DCI/NH3) m/e: 297 (M + H)+.   
2,3,6-Trimethoxyphenanthrene-9-carboxylic acid (7c) 
79% yield; white powder; mp 241-243 oC; 1H NMR (400.13 MHz) δ 8.93 (d, J=4Hz, 1H), 
8.33 (s, 1H), 7.84 (d, J=2Hz, 1H), 7.82 (s, 1H), 7.23 (s, 1H), 7.22 (dd, J=4Hz, 2Hz, 1H), 4.07 
(s, 3H), 3.98 (s,3H), 3.97 (s, 3H); MS (DCI/NH3) m/e: 314 (M + H)+.  
Methyl N-(2,3-methylenedioxy-6-benzyloxy-phenanthr-9-ylcarbonyl)-6-aminohexanoate 
(10) 
General procedure d from 7a (92%); cololess syrup; 1H NMR (400.13 MHz) δ 8.09 (d, 
J=4Hz, 1H), 7.81 (d, J=2Hz, 1H), 7.82 (s, 1H), 7.74 (d, J=4Hz , 2H), 7.45 (s, 1H), 7.33 (t, 
J=4Hz, 2H), 7.26 (m, 1H), 7.20 (dd, J= 4Hz, 2Hz, 1H), 7.09 (s, 1H), 6.03 (s, 2H), 5.18 (s, 
2H), 3.41(s, 3H), 3.28 (m, 2H), 2.28 (t, J = 6Hz, 2H), 1.61 (m, 2H), 1.56 (m, 2H), 1.38 (m, 
2H); MS (DCI/NH3) m/e: 500 (M + H)+.  
N-(2,3-methylenedioxy-6-benzyloxy-phenanthr-9-ylcarbonyl)-6-aminohexanoic acid 
(11) 
General procedure h from 10 (100%); white needles; mp 198-200 oC; 1H NMR (400.13 
MHz) δ 8.06 (d, J=4Hz, 1H), 7.79 (d, J=2Hz, 1H), 7.75 (s, 1H), 7.48 (s, 1H), 7.40 (d, J=4Hz, 
2H), 7.30 (t, J=4Hz, 2H), 7.23 (m, 1H), 7.16 (dd, J=4Hz, 2Hz, 1H), 7.09 (s, 1H), 6.00 (s, 2H), 
5.15 (s, 2H), 3.23 (m, 2H), 2.23 (t, J = 6Hz, 2H), 1.58 (m, 4H), 1.36 (m, 2H); MS (DCI/NH3) 
m/e: 486 (M + H)+.  
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-6-aminohexanoic acid (12) 
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General procedure e from 11 (90%); white powder, recrytallized from EtOH to give white 
needles; mp 184-186 oC; 1H NMR (400.13 MHz) δ 7.90 (d, J=4Hz, 1H), 7.87 (d, J=2Hz, 1H), 
7.77 (s, 1H), 7.60 (s, 1H), 7.44 (d, J=4Hz, 2H), 7.34 (t, J=4Hz, 2H), 7.30 (dd, J=4Hz, 2Hz, 
1H), 7.28 (m, 1H), 7.16 (s, 1H), 6.03 (s, 2H), 5.19 (s, 2H), 4.46 (s, 2H), 2.83 (m, 2H), 2.26 (t, 
J = 6Hz, 2H), 1.90 (m,2H), 1.68 (m, 2H), 1.28 (m, 2H); MS (DCI/NH3) m/e: 472 (M + H)+.    
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-5-aminohexanol (13) 
General procedure g from 10 (95%); white powder; mp 175-177 oC; 1H NMR (400.13 MHz) 
δ 7.90 (d, J=4Hz, 1H), 7.86 (d, J=2Hz, 1H), 7.76 (s, 1H), 7.45 (s, 1H), 7.44 (d, J=4Hz, 2H), 
7.32 (t, J=4Hz, 2H), 7.26 (m, 1H), 7.24 (dd, J=4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.03 (s, 2H), 
5.22 (s, 2H), 4.24 (s, 2H), 3.53 (t, J=6Hz, 2H), 2.72 (t, J=6Hz, 2H), 1.58 (m, 2H), 1.47 (m, 
2H), 1.29 (m, 4H); MS (DCI/NH3) m/e: 458 (M + H)+.    
Methyl N-(2,3-methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-5-aminopentanoate 
(14) 
General procedures d and e from 7a (93%); colorless syrup; 1H NMR (400.13 MHz) δ 7.97 
(d, J=4Hz, 1H), 7.83 (d, J=2Hz, 1H), 7.77 (s, 1H), 7.46 (s, 1H), 7.45 (d, J=4Hz, 2H), 7.35 (t, 
J=4Hz, 2H), 7.27 (m, 1H), 7.20 (dd, J=4Hz, 2Hz, 1H),7.07 (s, 1H), 6.01 (s, 2H), 5.17 (s, 2H), 
4.95 (s, 2H), 3.50(s, 3H), 3.01 (m, 2H), 2.42 (t, J=6Hz, 2H), 1.67 (m, 2H), 1.59 (m, 2H); MS 
(DCI/NH3) m/e: 472 (M + H)+.  
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-5-aminopentanoic acid (15) 
General procedure h from 14 (93%); white powder, recrystallized from EtOH to give white 
needles; mp 197-199 oC; 1H NMR (400.13 MHz) δ 7.89 (d, J=4Hz, 1H), 7.88 (d, J=2Hz, 1H), 
7.77 (s, 1H), 7.46 (s, 1H), 7.45 (d, J=4Hz , 2H), 7.34 (t, J=4Hz, 2H), 7.29 (dd, J= 4Hz, 2Hz, 
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1H),  7.27 (m, 1H), 7.16 (s, 1H), 6.05 (s, 2H), 5.21 (s, 2H), 4.42 (s, 2H), 2.89 (m, 2H), 2.27 (t, 
J=6Hz, 2H), 1.89 (m, 2H), 1.68 (m, 2H); MS (DCI/NH3) m/e: 458 (M + H)+.    
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylcarbonyl)-L-proline (16) 
General procedures d & h from 7a (95%); white powder; mp 221-223 oC; 1H NMR (400.13 
MHz) δ 8.00 (d, J=4Hz, 1H), 7.85 (d, J=2Hz, 1H), 7.81 (s, 1H), 7.46 (s, 1H), 7.45 (d, J=4Hz , 
2H), 7.36 (t, J=4Hz, 2H), 7.30 (m, 1H), 7.23 (dd, J= 4Hz, 2Hz, 1H), 7.13 (s, 1H), 6.04 (s, 
2H), 5.19 (s, 2H), 4.71 (t, J=7Hz, 1H), 3.62 (m, 2H), 2.21 (m, 2H), 1.83 (m, 2H); MS 
(DCI/NH3) m/e: 470 (M + H)+.  
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-L-proline methyl ester (17) 
General procedures d & e from 7a (85%); brown syrup; 1H NMR (400.13 MHz) δ 7.97 (d, 
J=4Hz, 1H), 7.83 (d, J=2Hz, 1H), 7.80 (s, 1H), 7.71 (s, 1H), 7.59 (d, J=4Hz, 2H), 7.47 (t, 
J=4Hz, 2H), 7.36 (m, 1H), 7.22 (dd, J= 4Hz, 2Hz, 1H), 7.11 (s, 1H), 6.06 (s, 2H), 5.20 (s, 
2H), 4.75 (s, 2H), 3.67 (s, 3H), 3.26 (d, J=17Hz, 1H), 2.45 (m, 2H), 1.96 (m, 2H), 1.68 (m, 
2H); MS (DCI/NH3) m/e: 470 (M + H)+.  
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-L-proline (18) 
General procedure h from 17 (100%); white powder; mp 147-149 oC; 1H NMR (400.13 
MHz) δ 8.11 (d, J=4Hz, 1H), 7.84 (d, J=2Hz, 1H), 7.75 (s, 1H), 7.42 (s, 1H), 7.40 (d, J=4Hz , 
2H), 7.30 (t, J=4Hz, 2H), 7.27 (m, 1H), 7.23 (dd, J= 4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.01 (s, 
2H), 5.16 (s, 2H), 4.30 (s, 2H), 3.24 (m, 1H), 2.48 (m, 2H), 2.0 (m, 2H), 1.68 (m, 2H); MS 
(DCI/NH3) m/e: 456 (M + H)+. Anal. (C28H25O5N·1.0H2O) C, H, N.  
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-L-prolinol (19) 
General procedure g from 17 (95%); colorless oil, recrystallization from EtOH gave white 
powder; mp 122-124 oC; 1H NMR (400.13 MHz) δ 8.13 (d, J=4Hz, 1H), 7.90 (d, J=2Hz, 1H), 
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7.84 (s, 1H), 7.51 (d, J=4Hz , 2H), 7.42 (s, 1H), 7.41 (t, J=4Hz, 2H), 7.34 (m, 1H), 7.29 (dd, 
J=4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.06 (s, 2H), 5.24 (s, 2H), 4.36 (d, J=7Hz, 2H), 3.78 (d, 
J=17Hz, 2H), 3.41 (m, 1H), 2.42 (m, 2H), 1.83 (m, 2H), 1.66 (m, 6H); MS (DCI/NH3) m/e: 
442 (M + H)+.    
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-L-2-piperidinecarboxylic 
acid (20) 
General procedures d, e & h from 7a (83%); white powder; mp 168-170 oC; 1H NMR 
(400.13 MHz) δ 8.26 (d, J=4Hz, 1H), 7.85 (d, J=2Hz, 1H), 7.77 (s, 1H), 7.56 (s, 1H), 7.45 (d, 
J=4Hz, 2H), 7.35 (t, J=4Hz, 2H), 7.30 (m, 1H), 7.26 (dd, J= 4Hz, 2Hz, 1H), 7.12 (s, 1H), 
6.05 (s, 2H), 5.20 (s, 2H), 4.24 (s, 2H), 3.16 (m, 1H), 2.26 (m, 2H), 1.80 (m, 2H), 1.64 (m, 
4H); MS (DCI/NH3) m/e: 470 (M + H)+.    
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-L-piperidinemethanol (21) 
General procedure g from 20 (95%); light brown oil, recrystallization from EtOH to gave 
white powder; mp 151-152 oC ; 1H NMR (400.13 MHz) δ 8.17 (d, J=4Hz, 1H), 7.89 (d, 
J=2Hz, 1H), 7.83 (s, 1H), 7.51 (d, J=4Hz, 2H), 7.43 (s, 1H), 7.40 (t, J=4Hz, 2H), 7.34 (m, 
1H), 7.27 (dd, J=4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.06 (s, 2H), 5.23 (s, 2H), 4.45 (d, J=7Hz, 2H), 
3.46 (d, J=17Hz, 2H), 2.85 (m, 1H), 2.37 (m, 2H), 1.69 (m, 6H); MS (DCI/NH3) m/e: 456 (M 
+ H)+.    
N-(2,3-Methylenedioxy-6-hydroxy-phenanthr-9-ylcarbonyl)-L-proline (22) 
General procedure f from 16 (92%); white powder; mp 230-231 oC; 1H NMR (400.13 MHz) 
δ 7.73 (d, J=4Hz, 1H), 7.67 (s, 1H), 7.50 (d, J=2Hz, 1H), 7.35 (s, 1H), 7.21 (dd, J=4Hz, 2Hz, 
1H), 7.06 (m, 1H), 6.01 (s, 2H), 4.67 (t, J=7Hz, 1H), 3.22 (m, 2H), 2.38 (m, 2H), 2.18 (m, 
2H), 1.86 (m, 2H); MS (DCI/NH3) m/e: 380 (M + H)+.   
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N-(2,3-Methylenedioxy-6-hydroxy-phenanthr-9-ylmethyl)-L-proline (23) 
General procedure f from 18 (95%); white powder; mp 205-206 oC; 1H NMR (400.13 MHz) 
δ 8.07 (d, J=4Hz, 1H), 7.82 (s, 1H), 7.80 (d, J=2Hz, 1H), 7.42 (s, 1H), 7.21 (dd, J=4Hz, 2Hz, 
1H), 7.10 (s, 1H), 6.04 (s, 2H), 4.09 (s, 2H), 3.16 (m, 1H), 2.38 (m, 2H), 2.23 (m, 2H), 1.95 
(m, 2H); MS (DCI/NH3) m/e: 366 (M + H)+.  
N-(2,3-Methylenedioxy-6-hydroxy-phenanthr-9-ylmethyl)-L-2-piperidinecarboxylic 
acid (24) 
General procedure f from 20 (95%); white powder; mp 211-213 oC; 1H NMR (400.13 MHz) 
δ 8.07 (d, J=4Hz, 1H), 7.80 (s, 1H), 7.76 (d, J=2Hz, 1H), 7.50 (s, 1H), 7.22 (dd, J= 4Hz, 2Hz, 
1H), 7.12 (s, 1H), 6.05 (s, 2H),4.06 (s, 2H), 3.12 (m, 1H), 2.38 (m, 2H), 1.88 (m, 2H), 1.64 
(m, 4H); MS (DCI/NH3) m/e: 380 (M + H)+.  
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylcarbonyl)-5-aminopentanoic acid (25) 
General procedures d & h from 7b (100%); white powder; mp 137-138 oC; 1H NMR (400.13 
MHz) δ 7.92 (d, J= 4Hz, 1H), 7.82 (s, 1H), 7.75 (s, 1H), 7.71 (d, J=2Hz, 1H), 7.13 (dd, 
J=4Hz, 2Hz, 1H), 7.09 (s, 1H), 6.00 (s, 2H), 3.89 (s, 3H), 3.23 (m, 2H), 2.23 (t, J=6Hz, 2H), 
1.58 (m, 4H); MS (DCI/NH3) m/e: 412 (M + H)+.  
Methyl N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-5-aminopentanoate 
(26) 
General procedures d & e from 7b (90%); colorless syrup; 1H NMR (400.13 MHz) δ 8.10 (d, 
J= 4Hz, 1H), 7.82 (s, 1H), 7.70 (d, J=2Hz, 1H), 7.52 (s, 1H), 7.12 (dd, J= 4Hz, 2Hz, 1H), 
7.08 (s, 1H), 6.04 (s, 2H), 3.89 (s, 3H), 3.80 (s, 2H), 3.56 (s, 3H), 2.80 (m, 2H), 2.33 (t, 
J=6Hz, 2H), 1.64 (m, 4H);  MS (DCI/NH3) m/e: 396 (M + H)+.   
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-5-aminopentanoic acid (27) 
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General procedure h from 26 (99%); white powder; mp 145-146 oC; 1H NMR (400.13 MHz) 
δ 8.06 (d, J=4Hz, 1H), 7.79 (s, 1H), 7.75 (d, J=2Hz, 1H), 7.48 (s, 1H), 7.22 (dd, J=4Hz, 2Hz, 
1H),  7.10 (s, 1H), 6.03 (s, 2H), 4.02 (s, 2H), 3.82 (s, 3H), 2.75 (m, 2H), 2.23 (t, J=6Hz, 2H), 
1.53 (m, 2H), 1.44 (m, 2H); MS (DCI/NH3) m/e: 382 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-5-aminopentanol (28) 
General procedure g from 27 (97%); colorless oil, recrystallization from EtOH gave white 
powder; mp 125-126oC; 1H NMR (400.13 MHz) δ 8.00 (d, J=4Hz, 1H), 7.76 (s, 1H), 7.72 (d, 
J=2Hz, 1H), 7.44 (s, 1H), 7.13 (dd, J= 4Hz, 2Hz, 1H), 7.05 (s, 1H), 6.04 (s, 2H), 3.95 (s, 2H), 
3.93 (s, 3H), 3.58 (t, J=6Hz, 2H), 2.75 (m, 2H), 1.55 (m, 2H), 1.44 (m, 2H), 1.30 (m, 2H); 
MS (DCI/NH3) m/e: 368(M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylcarbonyl)-L-proline (29) 
General procedures d & h from 7b (93%); white powder; mp 207-208 oC; 1H NMR (400.13 
MHz) δ 7.78(d, J= 4Hz, 1H), 7.70 (s, 1H), 7.54 (d, J=2Hz, 1H), 7.35 (s, 1H), 7.20 (dd, 
J=4Hz, 2Hz, 1H), 7.14 (m, 1H), 6.01 (s, 2H), 4.67 (m, 1H), 3.90 (s, 3H), 3.22 (m, 2H), 2.38 
(m, 2H), 1.86 (m, 2H); MS (DCI/NH3) m/e: 394 (M + H)+.    
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-proline methyl ester (30) 
General procedures d & e from 7a (85%); white syrup; 1H NMR (400.13 MHz) δ 8.20(d, 
J=4Hz, 1H), 7.80(s, 1H), 7.70 (d, J=2Hz, 1H), 7.52 (s, 1H), 7.21 (dd, J=4Hz, 2Hz, 1H), 7.13 
(s, 1H), 6.05 (s, 2H), 4.02 (s, 2H), 3.89 (s, 3H), 3.67 (s, 3H), 3.14 (m, 1H), 2.32 (m, 2H), 2.14 
(m, 2H), 1.86 (m, 2H); MS (DCI/NH3) m/e: 394 (M + H)+.  
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-proline (31) 
General procedure h from 30 (100%); white powder; mp 145-146 oC; 1H NMR (400.13 
MHz) δ 8.21 (d, J=4Hz, 1H), 7.77 (s, 1H), 7.72 (d, J=2Hz, 1H), 7.56 (s, 1H), 7.23 (dd, 
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J=4Hz, 2Hz, 1H), 7.10 (s, 1H), 6.04 (s, 2H), 4.05 (s, 2H), 3.96 (s, 3H), 3.16 (m, 1H), 2.36 (m, 
2H), 2.14 (m, 2H), 1.81 (m, 2H); MS (DCI/NH3) m/e: 380 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-prolinol (32) 
General procedure g from 31 (95%); white powder; mp 138-139 oC; 1H NMR (400.13 MHz) 
δ 8.16 (d, J=4Hz, 1H), 7.88(s, 1H), 7.80 (d, J=2Hz, 1H), 7.46 (s, 1H), 7.23 (dd, J=4Hz, 2Hz, 
1H), 7.14 (s, 1H), 6.07 (s, 2H), 4.03 (s, 2H), 3.94 (s, 3H), 3.70 (d, J=17Hz, 2H), 3.16 (m, 1H), 
2.38 (m, 2H), 2.23 (m, 2H), 1.95 (m, 2H); MS (DCI/NH3) m/e: 366 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-2-piperidinecarboxylic 
acid (33) 
General procedures d, e & h from 7b (80%); white powder; mp 171-172 oC; 1H NMR 
(400.13 MHz) δ 8.21 (d, J=4Hz, 1H), 7.77 (s, 1H), 7.72 (d, J=2Hz, 1H), 7.56 (s, 1H), 7.23 
(dd, J=4Hz, 2Hz, 1H), 7.10 (s, 1H), 6.04 (s, 2H), 4.08 (s, 2H), 3.96 (s, 3H), 3.08 (m, 1H), 
2.38 (m, 2H), 1.84 (m, 2H), 1.60 (m, 4H); MS (DCI/NH3) m/e: 394 (M + H)+.  Anal. 
(C23H23O5N·2.0H2O) C, H, N  
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-2-piperidinemethanol (34) 
General procedure g from 33 (98%); white powder; mp 155-157 oC; 1H NMR (400.13 MHz) 
δ 8.16 (d, J = 4Hz, 1H), 7.88 (s, 1H), 7.80 (d, J=2Hz, 1H), 7.47 (s, 1H), 7.22 (dd, J=4Hz, 
2Hz, 1H), 7.15 (s, 1H), 6.07 (s, 2H), 4.06 (s, 2H), 3.98 (s, 3H), 3.68 (d, J=7Hz, 2H), 2.87 (m, 
1H), 2.40 (m, 2H), 1.64 (m, 6H); MS (DCI/NH3) m/e: 380 (M + H)+.     
N-(2,3,6-Trimethoxyphenanthr-9-ylmethyl)-6-aminohexanoic acid (35) 
General procedures d, e & h from 7b (77%); brown powder; mp 133-134 oC; 1H NMR 
(400.13 MHz) δ 7.90 (d, J=4Hz, 1H), 7.78 (s, 1H), 7.72 (d, J=2Hz, 1H), 7.52 (s, 1H), 7.20 
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(dd, J=4Hz, 2Hz, 1H), 7.08 (s, 1H), 3.92 (s, 9H), 3.71 (s, 2H), 2.87 (m, 2H), 2.23 (m, 2H), 
1.55 (m, 2H), 1.46 (m, 2H), 1.28 (m, 2H); MS (DCI/NH3) m/e: 412 (M + H)+.  
N-(2,3,6-Trimethoxyphenanthr-9-ylmethyl)-5-aminohexanol (36) 
General procedure g from 35 (92%); yellow oil; 1H NMR (400.13 MHz) δ 7.88 (d, J=4Hz, 
1H), 7.76 (s, 1H), 7.71 (d, J=2Hz, 1H), 7.44 (s, 1H), 7.13 (dd, J=4Hz, 2Hz, 1H), 7.05 (s, 1H), 
5.99 (s, 2H), 3.94 (s, 9H), 3.80 (s, 2H), 3.73 (t, J=6Hz, 2H), 2.75 (m, 2H), 1.50 (m, 4H), 1.28 
(m, 4H); MS (DCI/NH3) m/e: 398 (M + H)+.  
N-(2,3,6-Trimethoxyphenanthr-9-ylmethyl)-L-2-piperidinecarboxylic acid (37) 
General procedures d, e & h from 7c (75%); light yellow powder; mp 187-188 oC; 1H NMR 
(400.13 MHz) δ 8.21 (d, J=4Hz, 1H), 7.78 (s, 1H), 7.71 (d, J=2Hz, 1H), 7.56 (s, 1H), 7.23 
(dd, J=4Hz, 2Hz, 1H), 7.10 (s, 1H), 4.10 (s, 2H), 3.98 (s, 9H), 3.12 (m, 1H), 2.42 (m, 2H), 
1.80 (m, 2H), 1.60 (m, 4H); MS (DCI/NH3) m/e: 410 (M + H)+.  
N-(2,3,6-Trimethoxyphenanthr-9-ylmethyl)-L-2-piperidinemethanol (38) 
General procedure g from 37 (95%); brown oil, recrystallization from EtOH gave yellow 
powder; mp135-137 oC; 1H NMR (400.13 MHz) δ 8.21 (d, J=4Hz, 1H), 7.78 (s, 1H), 7.72 (d, 
J=2Hz, 1H), 7.50 (s, 1H), 7.20 (dd, J=4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.07 (s, 2H), 4.10 (s, 2H), 
3.96 (s, 9H), 3.74 (d, J=17Hz, 2H), 2.87 (m, 1H), 2.41 (m, 2H), 1.66 (m, 6H); MS 
(DCI/NH3) m/e: 396 (M + H)+.  
1-[3-(4,5-Dimethoxy-2-nitrophenyl)-2-(4-methoxyphenyl)-acryloyl]-pyrrolidine-2-
carboxylic acid (39) 
General procedures d & h from 5b (90%); brown powder; mp 120-122 oC; 1H NMR (400.13 
MHz) δ7.67 (s, 1H), 7.26(d, J=4Hz, 2H), 7.08 (s, 1H), 6.73 (d, J=4Hz, 2H), 6.44 (s, 1H), 
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4.63 (t, J=7Hz, 1H), 3.92 (s, 6H), 3.73 (s, 3H), 3.41(t, J=7Hz, 2H), 2.22 (m, 2H), 1.92 (m, 
2H); MS (DCI/NH3) m/e: 443 (M + H)+.  
1-[3-(4,5-Dimethoxy-2-nitrophenyl)-2-(4-methoxyphenyl)-allyl]-pyrrolidine-2-
carboxylic acid (40) 
General procedure e from 39 (90%); brown syrup; 1H NMR (400.13 MHz) δ 7.61 (s, 1H), 
7.24 (d, J=4Hz, 2H), 7.01(s, 1H), 6.77 (d, J=4Hz, 2H), 6.64 (s, 1H), 4.36 (d, J=7Hz, 2H), 
3.89 (s, 3H), 3.72 (t, J=7Hz, 1H), 3.69 (s, 3H), 3.42 (s, 3H), 3.24 (m, 2H), 2.18 (m, 2H), 1.84 
(m, 2H); MS (DCI/NH3) m/e: 429 (M + H)+.  
{1-[3-(4,5-Dimethoxy-2-nitrophenyl)-2-(4-methoxyphenyl)-allyl]-pyrrolidin-2-yl}-
methanol (41) 
General procedure g from 40 (90%); dark oil; 1H NMR (400.13 MHz) δ 7.59 (s, 1H), 7.23 (d, 
J=4Hz, 2H), 7.00 (s, 1H), 6.71 (d, J=4Hz, 2H), 6.23 (s, 1H), 4.17 (d, J=7Hz, 2H), 3.89 (s, 
3H), 3.78 (d, J=7Hz, 2H), 3.69 (s, 3H), 3.58 (m, 1H), 3.41 (s, 3H), 3.16 (m, 2H), 1.91 (m, 
2H), 1.80 (m, 2H); MS (DCI/NH3) m/e: 415 (M + H)+.  
{1-[3-(3,4-Dimethoxyphenyl)-2-(4-methoxyphenyl)allyl]-pyrrolidin-2-yl}-methanol (42) 
Silmilar procedure as 40 (77% for two steps); yellow syrup; 1H NMR (400.13 MHz) δ 7.11 
(d, J=5Hz, 2H), 6.89 (d, J=5Hz, 2H), 6.63 (s, 1H), 6.58 (d, J=3Hz, 2H), 6.39 (s, 1H), 4.06 (d, 
J=7Hz, 2H), 3.90 (d, J=6Hz, 2H), 3.71 (s, 3H), 3.69 (s, 3H), 3.65 (m, 1H), 3.39 (s, 3H), 3.27 
(m, 2H), 1.84 (m, 2H), 1.70 (m, 2H); MS (DCI/NH3) m/e: 370 (M + H)+.  
3.6.4 Cell Growth Inhibition Assay 
The human A549 lung cancer cell line was used for the cytotoxicity screening of PBT 
derivatives using the cell-based sulforhodamine B (SRB) microtitre plate assay.8  Compound 
stock solutions were prepared in DMSO with the final solvent concentration ≤2% DMSO 
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(v/v), a concentration without effect on cell replication.  The cells were cultured at 37 oC in 
RPMI-1640 supplemented with 25 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
(HEPES), 2% (w/v) sodium bicarbonate, 10% (v/v) fetal bovine serum, and 100 µg/mL 
kanamycin in a humidified atmosphere containing 5% CO2.  Duration of compound exposure 
was 3 days.  The ED50 value (the concentration that reduced the cell number by 50%) was 
interpolated from dose-response data.  Each test was performed in triplicate with variation 
less than 5%.  The EC50 values determined in each independent test varied less than 10%.
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Table 3-1.  Cytotoxicity of 2,3-Methylenedioxy-6-alkyloxy-9-substituted PBT Analogs 
R2
R1O
O
O 2
3
6
9
 
Compound R1 R2 EC50  (µM)a,b
7a -CH2C6H5 -COOH NA 
7b -CH3 -COOH NA 
10 -CH2C6H5 -CONH(CH2)5COOMe 41.2 
11 -CH2C6H5 -CONH(CH2)5COOH 41.2 
12 -CH2C6H5 -CH2NH(CH2)5COOH 1.6 
13 -CH2C6H5 -CH2NH(CH2)5CH2OH 1.1 
14 -CH2C6H5 -CH2NH(CH2)4COOMe 17.0 
15 -CH2C6H5 -CH2NH(CH2)4COOH 2.2 
16 -CH2C6H5 N
O
HOOC
 
42.6 
17 -CH2C6H5 N
MeOOC
 
32.1 
18 -CH2C6H5 N
HOOC
 
4.4 
 43
19 -CH2C6H5 N
HO
 
1.8 
20 -CH2C6H5 N
HOOC
 
3.2 
21 -CH2C6H5 N
HO
 
1.3 
22 -H N
O
HOOC
 
39.7 
23 -H 
N
HOOC
 
41.2 
24 -H N
HOOC
 
39.7 
25 CH3 -CONH(CH2)4COOH 73.3 
26 CH3 -CH2NH(CH2)4COOMe 25.3 
27 CH3 -CH2NH(CH2)4COOH 1.3 
28 CH3 -CH2NH(CH2)4CH2OH 0.27 
29 CH3 N
O
HOOC
 
5.3 
30 CH3 N
MeOOC
 
73.8 
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31 CH3 N
HOOC
 
2.1 
32 CH3 N
HO
 
0.7 
33 CH3 N
HOOC
 
0.5 
34 CH3 N
HO
 
0.16 
aEtoposide (VP-16) used as positive control, EC50 = 1.4 µM.  bNA = Not Active 
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Table 3-2.  Cytotoxicity of 2,3,6-Trimethyoxy-9-substituted PBT Analogs 
R
H3CO
OCH3
H3CO 2
3
6
9
 
Compound R EC50  (µM) 
7c -COOH NA 
35 -CH2NH(CH2)5COOH 9.7 
36 -CH2NH(CH2)5CH2OH 2.7 
37 N
HOOC
 
9.7 
38 
N
HO
 
6.3 
aEtoposide (VP-16) used as positive control, EC50 = 1.4 µM.  bNA = Not Active 
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Table 3-3.  Cytotoxicity of seco-PBT Analogs 
 
Compound Structure EC50  (µM) 
39 
MeO
MeO OMe
N
NO2
O
HOOC
 
80 
40 
MeO
MeO OMe
N
NO2
HOOC
 
45.2 
41 
MeO
MeO OMe
N
NO2
HO
 
11.7 
42 
MeO
MeO OMe
NHO
 
52.2 
Etoposide (VP-16) used as positive control, EC50 = 1.4 µM 
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4 CHAPTER IV.  DESIGN, SYNTHESIS AND CYTOTOXIC 
EVALUATION OF 9-SUBSTITUTED PHENANTHRENE-
BASED TYLOPHORINE DERIVATIVES (PBTS) (PART II) 
 
 
4.1 INTRODUCTION 
Chapter III reported the design, synthesis and cytotoxicity evaluation of a series of novel 
polar water-soluble phenanthrene-based tylophorine derivatives (PBTs) with EC50 ≅10-7 M 
against the A549 human lung cancer cell line.  These compounds could possibly have lower 
or no CNS toxicity because the increased polarity should prevent them from penetrating the 
blood-brain barrier.  Preliminary structure-activity relationship (SAR) studies revealed that 
2,3-methylenedioxy-6-methoxyphenanthrene was an optimized core structural unit that 
incorporated all of the favorable modifications identified at the C-2, C-3 and C-6 positions.  
A N-containing substituent at the C-9 position is also required for cytotoxic activity, and this 
site presents an ideal position for introducing more polar, water-solubility-enhancing 
moieties, such as a terminal hydroxyl or carboxylic acid.  These critical SAR clues prompted 
us to explore additional C-9 substituents to better understand the SAR of the PBT compound 
class.  Most importantly, we wanted to extend the in vitro anticancer spectra to include 
additional significant tumor types as well as investigate whether target PBTs exhibit cross-
resistance in a multi-drug resistant cancer cell subline. 
In this Chapter, we describe new developments toward the design and synthesis of novel 
C-9 substituted PBTs.  Several N-containing cyclic and acyclic terminal-hydoxyl moieties 
 
were introduced at the C9 position in order to explore and optimize the activity profiles of 
novel C-9 substituted PBTs.  All compounds were evaluated as in vitro anticancer agents 
against the human A549 lung cancer cell line. Several C9-substituted PBTs showed superior 
cytotoxic activity profiles with EC50 values in the sub-micromolar range, indicating that 
rational C-9 modification was an effective approach to optimize the activity profile of this 
compound class.  The active compounds were further examined against DU-145 (prostate), 
ZR-751 (breast), KB (nasopharyngeal), and KB-Vin (multi-drug resistant KB subline) human 
cancer cell lines.  Finally, the SAR is discussed relative to the current issues of 
chemotherapy-induced toxicity and resistance. 
4.2 DESIGN AND SYNTHESIS 
MeO
COOH
O
O
MeOO
O
O
O
MeO
COOH
COOH
CHO
NO2
a b c
Reagents and conditions: a: Ac2O/Et3N b: FeSO4/NH4OH c: NaNO2/Fluoroboric acid; Ferrocene/acetone 
d; EDC,DMAP,HOBt/DMF e: BMS/THF f: NaOH/MeOH (1:1) g: LiAlH4/THF
II.
IV. V.
NO2
O
O
MeO
COOH
NH2
MeO
O
O
R
O
MeO
O
O
R
d e or f or g
VII.VI.
I.
III.
 
Scheme 4-1. Synthesis of 6-methoxy-9-substituted PBTs. 
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4.3 CHEMISTRY 
Compounds 43-56 were synthesized from commercially available 3,4-methylenedioxy-
6-nitrobenzaldehyde and 4-methoxyphenylacetic acid according to the methods we described 
in Chapter III (compounds 57 and 58 were synthesized using similar procedures). Briefly, 
2,3-methylenedioxy-6-methoxy-phenanthrene-9-carboxylic acid (V) was obtained through a 
Perkin reaction and an improved free-radical Pschorr cyclization (Scheme 4-1)1-2 in a 
satisfactory overall yield of 78%. Compound V was then condensed with the appropriate 
amines in the presence of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride 
(EDC), 4-(dimethylamino) pyridine (DMAP) and 1-hydroxybenzotriazole (HOBT) (Scheme 
4-1).  The carbonyl bond of the amide was reduced with borane-methyl sulfide complex 
(BMS) to give the methylene amines and then the target carboxylic acid and hydroxymethyl 
analogs were produced by basic hydrolysis and lithium aluminum hydride (LiAlH4) 
reduction, respectively.  
4.4 RESULTS AND DISCUSSION 
The new target compounds (43-58), together with 20, 21, 27, 28, 31-34 from the 
previous chapter, were first evaluated for in vitro anticancer activity against the human A549 
lung cancer cell line using the cell-based sulforhodamine B (SRB) microtitre plate assay.3  
Compound structures and cytotoxic activity data are shown in Tables 4-1 and -2.  Twelve 
active compounds were further evaluated against three additional cancer cell lines (KB, 
DU145 and ZR-751) and one resistant subline (KB-Vin) (Table 4-3).  Antofine, emetine, 
doxorubicin and etoposide (VP-16) were used as reference compounds.   
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4.4.1 Structure-Activity Relationship (SAR) Studies 
Interestingly, changing the stereochemistry of the 2’-substituent on the pyrrole ring 
altered the potency.  Compounds 31 and 32 were more potent that their stereoisomers 43 and 
44.  These findings are consistent with those from earlier studies of tylophorine alkaloids that 
showed equal or higher cytotoxicity of the 13aS series as compared with the 13aR series,4 
suggesting a well-defined regioselective interaction of these compounds with the putative 
biological target. 
For target compounds with varied acyclic N-containing side chains, the distance between 
the nitrogen and terminal substituent affected the potency.  The aminoundecanoic acid analog 
was significantly less active than the corresponding aminopentanoic acid, which in turn was 
slightly less active than the aminohexanoic acid (49 < 27 < 45).  A similar rank order of 
potency was found when the terminal carboxylic acid was reduced to a hydroxymethyl group 
(50 < 28 < 46).  The shorter spacing was definitely preferable to the longer spacing. 
Based on the significant biological activity of the acylic amines, the position of the 
piperidine substituent was changed from 2’ (ortho) to 4’ (para), which resulted in increased 
potency (33 vs 47; 34 vs 48), demonstrating that a terminal hydroxyl/carboxylic acid in a 
para position could favorably affect the activity.  This conclusion was confirmed for 
compounds where the C-6 methoxy group was replaced with a benzyloxy ether (Table 4-2; 
57 > 20 and 58 > 21). 
To investigate the relationship between activity and nitrogen content in the C-9 side 
chain, both piperidine (one nitrogen) and piperazine (two nitrogens) analogs were prepared 
and tested.  Although the second nitrogen was tolerated, its presence slightly decreased 
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activity [compare the EC50 values between the piperazine-ethanol (54) and piperidine-ethanol 
(56) analogs].  
Additional SAR observations relative to the C-9 N-containing side chain were also noted 
in the course of our study. 4’-Hydroxymethyl and 4’hydroxyethylpiperidine analogs (48 and 
56, respectively) were both quite potent, but the former was more active than the latter.  
While the piperazine-ethanol analog (54) was quite active, the piperazine-ethoxyethanol 
analog (55) lost all activity.  In contrast, potency was increased when the hydroxylethyl of 54 
was replaced with a phenol in 53.  These results corroborate the conclusion that an 
appropriate side chain length is important for maximal activity.   
Since compound 53 was quite potent, while both ortho- and para-chlorophenyl 
substituted piperazine analogs (51, 52) were inactive, the presence of a hydrogen bond 
acceptor/donor group at C-9 chain terminus appears essential for cytotoxic activity.  It could 
be that a hydrogen bonding interaction between the terminal group and a biological target 
plays an important role in binding the hypothetical target, and the spacing between this group 
and the remainder of the molecule needs to be well optimized.   
4.4.2 Drug-Resistance Study 
Twelve active compounds [including four hydrochloride salts (34-HCl, 46-HCl, 48-HCl, 
56-HCl) of corresponding active free bases (34, 46, 48, 56)] were further screened against an 
extended panel of human tumor cell lines including DU-145 (prostate), ZR-751 (breast), KB 
(nasopharyngeal), and KB-VIN (multidug-resistant KB subline) in order to explore their 
antitumor spectra and drug-resistance profiles. Four compounds were used as reference 
compounds.  Antofine is a positional isomer of tylophorine isolated from Asclepiadaceae by 
Dr. T. S. Wu5 in Taiwan.  Emetine is a protein synthesis inhibitor, which exhibits cross-
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resistance with tylocrebine in mutant CHO cells.3 Doxorubicin (adriamycin), vincristine, and 
etoposide (VP-16, Vepesid®) are widely used anticancer agents for treating a range of solid 
tumors.  The results are illustrated in Table 4-3.  In general, all new compounds exhibited 
potent activity against KB (EC50: 0.07-0.50 µM), DU-145 (EC50: 0.03-0.67 µM), and ZR-751 
(EC50: 0.02-0.54 µM) cell lines, as well as KB-Vin (EC50: 0.09-0.38 µM) cells. The 
corresponding salts showed similar selectivity pattern and slightly better potency than the 
free bases, possibly due to improved water solubility. Compared to the reference compounds 
emetine, doxorubicin, etoposide and vincristine, neither the C-9 substituted PBTs nor 
antofine showed any cross-resistance with the KB-Vin resistant cell line, suggesting that their 
mode may be distinctly different from that of other cancer chemotherapeutic compounds. All 
PBTs exhibited cytotoxic activity in the sub-micromolar range against the limited set of 
representative human cancer cell lines.  Compound 46-HCl was most active against DU-145 
(prostate) and ZR-751 (breast) cancer cell lines, and compound 48-HCl exhibited a fairly 
uniform and potent cytotoxic activity with ED50 values less than 100 nM against the tumor 
cell line panel. Compound 56 and its HCl salt (56-HCl) were most active against ZR-751 
breast cancer cell replication, suggesting that further exploration of this compound as a 
selective breast cancer drug lead will be worthwhile. 
In summary, a series of novel 9-substituted 2, 3-methylenedioxy-6-methoxy-PBTs were 
synthesized and exhibited potent cytotoxic activity against a limited but diverse panel of 
human tumor cell lines, including a multidrug-resistant variant.  The EC50 values were in the 
sub-micromolar range, comparable with the activity of the two front-line antineoplastic drugs 
used as positive controls, and the new compounds had a superior drug-resistance profile. 
Combination of a 2, 3-methylenedioxy-6-methoxyphenanthrene skeleton with a C-9 cyclic 
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piperidine ring and para terminal hydroxyl side chain generated the most potent PBTs.  N-
(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-4-piperidinemethanol (48) 
exhibited a fairly uniform and potent cytotoxic activity with EC50 values less than 100 nM 
against the cell line panel. The activity was maintained and the water solubility increased by 
formation of the hydrochloride salt.  These PBT salts are the first reported water soluble 
tylophorine derivatives with significant cytotoxic activity, in particular to multidrug-resistant 
cells.  They represent well-qualified and promising clinical trial candidates for cancer 
(especially refractory cancer) treatment.  
4.5 CONCLUSIONS 
More than 70 PBTs were designed and synthesized. All compounds were screened 
against human cancer cell lines.  The most active compounds which incorporated all of the 
favorable modifications identified to date possess novel structures and showed remarkable 
EC50 values in the sub-micromolar range, and displayed notable selectivity.  These 
derivatives are the first reported water soluble tylophorine derivatives with remarkable 
cytotoxic activity, in particular to multidrug-resistant cells.  They represent well-qualified 
and promising clinical trial candidates for cancer (especially refractory cancer) treatment.  
4.6 EXPERIMENTAL SECTION 
4.6.1 Instruments and Chemicals 
Melting points were measured using Fisher Johns melting apparatus without correction. 
The proton nuclear magnetic resonance (1H NMR) spectra were measured on a 300 MHz 
Varian Gemini 2000 spectrometer using TMS as internal standard. Mass spectra were 
recorded on a PE-Sciex API-3000 LC/MS/MS instrument equipped with a Turbo IonsSpray 
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ion source. The solvent used was CDCl3 unless indicated. Elemental analyses were 
performed by Atlantic Microlab, Inc., Norcross, GA. All active target compounds were 
analyzed for C, H, N and gave values within +0.4% of the theoretical values.  The purity of 
inactive target compounds was verified by HPLC using three different solvent systems. Thin-
layer chromatography (TLC) was performed on PLC silica gel 60 F254 plates (0.5 mm, 
Merck). Biotage Flash+ and Isco Companion systems were used as medium-pressure column 
chromatography. Silica gel (200-400 mesh) from Aldrich, Inc., was used for column 
chromatography. 4-benzyloxyphenylacetic acid and 3,4-Methylenedioxy-6-
nitrobenzaldehyde were purchased from TCI.  Isonipecotic acid and L-pipecolinic acid were 
commercially available from Lancaster. All other chemicals were obtained from Aldrich, Inc. 
and Fisher, Inc.  
4.6.2 Chemistry 
4,5-Methylenedioxy-(4-methoxyphenyl)-2-nitrocinnamic acid (III in Scheme 4-1) 
A solution of 3,4-methylenedioxy-6-nitrobenzaldehyde (12 mmol), NEt3 (12 mmol), 4-
methoxyphenylacetic acid (17 mmol) was refluxed with stirring under Ar for 40 min. 20 
Water (30 ml) was added to the reaction mixture and during the addition the temperature was 
maintained between 90 °C and 100 °C. The reaction mixture was cooled to ambient 
temperature and solid was collected by filtration and recrystallized from EtOH. 
91% yield; yellow powder; mp 184-185 °C; 1H NMR (400.13 MHz) δ 7.92 (s, 1H), 7.53 (s, 
1H), 7.01 (d, J = 2Hz, 2H), 6.73 (d, J = 2 Hz, 2H), 6.22 (s, 1H), 5.96 (s, 2H), 3.74 (s, 3H); 
MS (DCI/NH3) m/e: 344 (M + H)+.  
4,5-Methylenedioxy-(4-methoxyphenyl)-2-aminocinnamic acid (IV in Schem 4-1) 
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To a solution of the acid (III) (7 mmol) in 10% aqueous NH4OH (100 ml) was added ferrous 
sulfate heptahydrate (15 g) dissolved in distilled water (100 ml) and concentrated aqueous 
NH4OH (100 ml). The reaction mixture was refluxed for 1.5 h, cool to 40 °C and filtrate on 
Celite and acidified with acetic acid (100 ml), the solid was collected by filtration and 
recrystallization from EtOH yielded the aminostilbenic acid. 
95% yield; yellow powder; mp 165-166 °C; 1H NMR (400.13 MHz) δ  7.74(s, 1H), 7.08 (d, J 
= 2Hz, 2H), 6.80 (d, J = 2 Hz, 2H), 6.17 (s, 1H), 6.06 (s, 1H), 5.70 (s, 2H), 3.80 (s, 2H), 3.73 
(s, 3H); MS (DCI/NH3) m/e: 314 (M + H)+.   
2,3-Methylenedioxy-6-methoxy-phenanthrene-9-carboxylic acid (V in Scheme 4-1) 
A solution composed of the aminostilbenic acid (IV) (3 mmol), NaOH (33 mmol) and 
NaNO2 in water (10 ml) was added dropwise over 30 min with stirring to 48% fluoroboric 
acid (43 mmol) at 0-5 °C. The mixture was stirred for 1 h after which sulfamic acid was 
added until the mixture tested negative to starch-iodide paper. The crude solid was collected 
by filtration, dissolved in anhydrous acetone (10 ml) and then added dropwise with stirring 
over a 15 min period to ferrocene (0.056 g, 0.3 mmol) in acetone at ambient temperature. 
After an additional 15 min of stirring the green reaction mixture was added to water (100 ml). 
A light-yellow precipitate was collected and the trace amount of ferrocene was removed in 
vacuo to afford the phenanthroic acid. 
92% yield; white powder; mp 293-295 oC; 1H NMR (400.13 MHz) δ 7.67 (s, 1H), 7.60 (d, J= 
4Hz, 1H), 7.22 (dd, J= 4Hz, 2Hz, 1H), 6.92 (s, 1H), 6.89 (d, J=2Hz, 1H), 6.70 (s, 1H), 5.98 
(s, 2H), 3.79 (s,3H); MS (DCI/NH3) m/e: 297 (M + H)+.   
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4.6.3 General Procedures 
General Procedure for the protection of cycloalkylamino acid: 
To a solution of cycloalkylamino acid (4 mmol) in dry MeOH (4 ml) was added 
dropwise SOCl2 (0.4 ml) at -30 °C. The reaction mixture was warmed to room temperature 
and refluxed for 1 h. Then the solvent was removed in vacuo and the product was used in the 
next reaction without any further purification. 
General Procedure for the protection of acyclic alkylamino acid: 
To a solution of dry MeOH (3 ml) was added dropwise AcCl (0.45 ml) at 0 °C. After 10 
min stirring, the amino acid was added to the solution in portions. The mixture was warmed 
to room temperature and refluxed for 2 h, then the solvent was removed in vacuo and the 
product was used in the next reaction without any further purification. 
General Procedure for the peptide bond condensation reaction (d): 
To a solution of phenanthroic acid (4 mmol), 4-(dimethylamino) pyridine (DMAP) (2 
mmol), 1-hydroxybenzotriazole (HOBT) (4 mmol) and methyl protected amino acid (4.4 
mmol) in 20 ml DMF was added NMM (1.03 ml). The mixture was stirring at 0 °C for 15 
min, N-(3-dimethylaminopropyl)-N'- ethylcarbodiimide hydrochloride (EDC) (4.4 mmol) 
was added by portion. The reaction mixture was stirred overnight at room temperature and 
partitioned between EtOAc and water. The organic layer was washed with brine, saturated 
NaHCO3 and1N HCl, dried over Na2SO4, and concentrated in vacuo. The crude product was 
chromatographed using Biotage Flash+ and Isco Companion systems using a 40g silica 
cartridge and EtOAc/hexane as eluant. 
General Procedure for the carbonyl reduction reaction (e): 
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To a stirred solution of 9-ylcarbonyl compound (2 mmol) in THF (20 ml) was added 
dropwise borane-methyl sulfide (BMS)(4 ml, 2.0M solution in THF), the reaction was stirred 
at room temperature overnight and quenched with 1N HCl. THF was removed in vacuo. The 
residue was partitioned between CH2Cl2 and water. The organic layer was dried, filtered and 
evaporated to afford 9-ylmethyl ester. The crude product was chromatographed using 
Biotage Flash+ and Isco Companion systems using MeOH/CH2Cl2 as eluant. 
General Procedure for the basic hydrolysis reaction (f): 
A solution of ester, 4N NaOH and MeOH (1:1) was refluxed for 4 h. The reaction 
mixture was acidified and partitioned between 10% MeOH/CH2Cl2 and 1N HCl, The organic 
layer was dried over Na2SO4, filtered and evaporated. The crude product was 
chromatographed using Biotage Flash+ and Isco Companion systems using MeOH/CH2Cl2 
as eluant. 
General Procedure for the LiAlH4 reduction (g): 
To a suspension of methyl ester (1 mmol) in 15 ml dry THF was added LiAlH4 (1 g) in 
portions at 0 °C. After addition, the reaction mixture was refluxed for 4 h, and then cooled to 
0 °C. The reaction mixture was quenched with MeOH, and then 10% Rochelle salt was 
added. The reaction mixture was extracted with water and 10% MeOH/CH2Cl2. The organic 
layer was dried over Na2SO4, and the crude product was chromatographed using Biotage 
Flash+ and Isco Companion systems using MeOH/CH2Cl2 as eluant. The product was 
partitioned between water and 10% MeOH/CH2Cl2. Organic layer was dried over Na2SO4, 
and the crude product was chromatographed using Biotage Flash+ and Isco Companion 
systems using MeOH/CH2Cl2 as eluant. 
General Procedure for making hydrochloride salts: 
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To a suspension of the free base (3 mmol) in EtOH (15 ml) was added dropwise an 
equivalent of 6N HCl.  After the free base was well dissolved, the solvent was removed in 
vacuo and the remaining hydrochloride salt was dried over phosphorus pentoxide.    
The physical and spectral data for 20, 21, 27, 28, and 31-34 were reported in Chapter III. 
4.6.4 Chemistry 
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-2-piperidinemethanol 
hydrochloride (34-HCl) 
mp 193-194 °C; 1H NMR (400.13 MHz) δ 8.14 (d, J=4Hz, 1H), 8.00 (s, 1H), 7.78 (d, J=2Hz, 
1H), 7.49 (s, 1H), 7.20 (dd, J=4Hz, 2Hz, 1H), 7.15 (s, 1H), 6.04 (s, 2H), 4.20 (s, 2H), 3.90 (s, 
3H), 3.72 (d, J=17Hz, 2H), 3.04 (m, 1H), 2.68 (m, 2H), 1.83 (m, 6H); MS (DCI/NH3) m/e: 
380 (M + H)+.  Anal. (C23H25O4N·1.0HCl·2.0H2O) C, H, N,  
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-D-proline (43) 
General procedures d, e & f from V (81%); white powder; p 152-153 °C; 1H NMR (400.13 
MHz) δ 8.21 (d, J=4Hz, 1H), 7.77 (s, 1H), 7.72 (d, J=2Hz, 1H), 7.56 (s, 1H), 7.23 (dd, 
J=4Hz, 2Hz, 1H), 7.10 (s, 1H), 6.04 (s, 2H), 4.05 (s, 2H), 3.96 (s, 3H), 3.16 (m, 1H), 2.36 (m, 
2H), 2.14 (m, 2H), 1.81 (m, 2H); MS (DCI/NH3) m/e: 380 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-D-prolinol (44) 
General procedure g from 43 (95%); yellow syrup, recrystalization from EtOH gave white 
powder; mp 130-132 °C; 1H NMR (400.13 MHz) δ 8.16 (d, J=4Hz, 1H), 7.88(s, 1H), 7.80 (d, 
J=2Hz, 1H), 7.46 (s, 1H), 7.23 (dd, J=4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.07 (s, 2H), 4.03 (s, 2H), 
3.94 (s, 3H), 3.70 (d, J= 17Hz, 2H), 3.16 (m, 1H), 2.38 (m, 2H), 2.23 (m, 2H), 1.95 (m, 2H); 
MS (DCI/NH3) m/e: 366 (M + H)+.     
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N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-6-aminohexanoic acid (45) 
General procedures d, e & f from V (78%); white powder; mp 167-169 °C; 1H NMR (400.13 
MHz) δ 7.88 (d, J=4Hz, 1H), 7.76 (s, 1H), 7.71 (d, J=2Hz, 1H), 7.44 (s, 1H), 7.13 (dd, 
J=4Hz, 2Hz, 1H), 7.05 (s, 1H), 5.99 (s, 2H), 3.87 (s, 2H), 3.82 (s, 3H), 2.75 (m, 2H), 2.23 (t, 
J=6Hz, 2H), 1.53 (m, 2H), 1.44 (m, 2H), 1.28 (m, 2H); MS (DCI/NH3) m/e: 396 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-6-aminohexanol (46) 
General procedure g from 45 (90%); light green syrup, recrystalization from EtOH gave pale 
green powder; mp 145-147 °C; 1H NMR (400.13 MHz) δ 7.90 (d, J =4Hz, 1H), 7.84 (s, 1H), 
7.78 (d, J=2Hz, 1H), 7.51 (s, 1H), 7.21 (dd, J=4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.03 (s, 2H), 4.34 
(s, 2H), 3.94 (s, 3H), 3.48 (t, J=6Hz, 2H), 2.76 (m, 2H), 1.58 (m, 2H), 1.45 (m, 2H, 1.26 (m, 
2H), 1.20(m, 2H); MS (DCI/NH3) m/e: 382 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-6-aminohexanol 
hydrochloride (46-HCl) 
White powder; mp 187-188°C; 1H NMR (400.13 MHz) δ δ 8.14 (d, J=4Hz, 1H), 7.82 (s, 1H), 
7.76 (d, J=2Hz, 1H), 7.50 (s, 1H), 7.18 (dd, J=4Hz, 2Hz, 1H), 7.13 (s, 1H), 6.08 (s, 2H), 4.67 
(s, 2H), 3.98 (s, 3H), 3.60 (t, J=6Hz, 2H), 3.44 (m, 2H), 1.66(m, 2H), 1.59 (m, 2H), 1.40 (m, 
2H), 1.33 (m, 2H), ; MS (DCI/NH3) m/e: 382 (M + H)+.  Anal. (C23H27O4N·1.0HCl·1.5H2O) 
C, H, N. 
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-4-piperidinecarboxylic 
acid (47) 
General procedures d, e & f from V (85%); light yellow powder; mp 238-240 °C; 1H NMR 
(400.13 MHz) δ 8.30 (d, J=4Hz, 1H), 7.92 (s, 1H), 7.83 (d, J=1Hz, 1H), 7.42 (s, 1H), 7.22 
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(dd, J=4Hz, 2,4Hz, 1H), 7.17 (s, 1H), 6.09 (s, 2H), 4.04 (s, 2H), 3.66 (s, 3H), 2.98 (m, 1H), 
2.58 (m, 4H), 1.75 (m, 4H); MS (DCI/NH3) m/e: 394 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-4-piperidinemethanol (48) 
General procedure g from 47 (92%); light green syrup, recrystallization from EtOH gave 
white powder; mp 130-132 °C; 1H NMR (400.13 MHz) δ  8.26 (d, J=4Hz, 1H), 7.87 (s, 1H), 
7.78 (d, J=2Hz, 1H), 7.38 (s, 1H), 7.19 (dd, J=4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.05 (s, 2H), 3.97 
(s, 3H), 3.81(s, 2H), 3.43 (d, J=7Hz, 2H), 2.97 (m, 2H), 2.02 (m, 2H), 1.65 (m, 2H), 1.48 (m, 
1H), 1.26 (m, 2H); MS (DCI/NH3) m/e: 380 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-L-4-piperidinemethanol 
hydrochloride (48-HCl) 
White powder; mp 256-258 °C; 1H NMR (400.13 MHz) δ 8.00 (d, J=4Hz, 1H), 7.85 (s, 1H), 
7.82 (s, 1H), 7.77 (d, J=2Hz, 1H), 7.22 (dd, J=4Hz, 2Hz, 1H), 7.20 (s, 1H), 6.03 (d, J=4Hz, 
2H), 4.59 (s, 2H), 3.92 (s, 3H), 3.46 (d, J=4Hz, 2H), 3.31 (m, 2H), 2.77 (m, 2H), 1.76 (m, 
4H), 1.68 (m, 1H); MS (DCI/NH3) m/e:380 (M + H)+.  Anal. (C23H25O4N·1.0HCl·1.0H2O) C, 
H, N.  
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-11-aminoundecanoic acid 
(49) 
General procedures d, e & f from V (75%); white powder; mp 146-148 °C; 1H NMR (400.13 
MHz) δ 7.98 (d, J=4Hz, 1H), 7.80 (s, 1H), 7.72 (d, J=2Hz, 1H), 7.50 (s, 1H), 7.11 (dd, 
J=4Hz, 2Hz, 1H), 7.06 (s, 1H), 6.05 (s, 2H), 4.02 (s, 3H), 3.86 (s, 2H), 2.93 (m, 2H), 2.2 (m, 
2H), 1.67 (m, 2H), 1.53 (m, 2H), 1.21 (m, 12H); MS (DCI/NH3) m/e: 466 (M + H)+.   
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-6-aminoundecanol (50) 
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General procedure g from 49 (90%); light green syrup, recrystalization from EtOH gave pale 
green powder; mp 122-124 °C; 1H NMR (400.13 MHz) δ 7.86 (d, J=4Hz, 1H), 7.67 (s, 1H), 
7.40 (d, J=2Hz, 1H), 7.43 (s, 1H), 7.18 (dd, J=4Hz, 2Hz, 1H), 7.08 (s, 1H), 6.01 (s, 2H), 4.32 
(s, 2H), 3.88 (s, 3H), 3.68 (t, J=6Hz, 2H), 2.86 (m, 2H), 1.68 (m, 2H), 1.58 (m, 2H), 1.26 (m, 
14H); MS (DCI/NH3) m/e: 452 (M + H)+.     
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-(2-chlorophenyl)-piperazine 
(51) 
General procedures d & e from V (87%); white powder; mp 196-198 °C; 1H NMR (400.13 
MHz) δ 8.32 (d, J=4Hz, 1H), 7.91 (s, 1H), 7.81 (d, J=2Hz, 1H), 7.44 (s, 1H), 7.32 (dd, 
J=4Hz, 2 Hz, 1H), 7.22 (d, J=9Hz, 1H), 7.18 (s, 1H), 7.16 (d, J=9Hz, 1H), 7.00 (m, 1H), 6.93 
(m, 1H), 6.08 (s, 2H), 4.30 (s, 2H), 3.94 (s, 3H), 3.68 (t, J=6Hz, 4H), 3.05 (m, 4H); MS 
(DCI/NH3) m/e: 461.5 (M + H)+.    
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-(4-chlorophenyl)-piperazine 
(52) 
General procedures d & e from V (80%); white powder; mp 222-223 °C; 1H NMR (400.13 
MHz) δ 8.30 (d, J=4Hz, 1H), 7.90 (s, 1H), 7.81 (d, J=2Hz, 1H), 7.50 (s, 1H), 7.22 (dd, 
J=4Hz, 2Hz, 1H), 7.19 (s, 1H), 7.17 (d, J=9Hz, 2H), 6.89 (d, J=9Hz, 2H), 6.09 (s, 2H), 4.68 
(s, 2H), 3.90 (s, 3H), 3.65 (t, J=8Hz, 4H), 3.14 (m, 4H); MS (DCI/NH3) m/e: 461.5 (M + H)+.   
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-(4-hydroxyphenyl)-
piperazine (53) 
General procedures d & e from V (82%); white powder; mp 225-227 °C; 1H NMR (400.13 
MHz) δ 8.10 (d, J=4Hz, 1H), 7.90 (s, 1H), 7.82 (d, J= 2Hz, 1H), 7.49 (s, 1H), 7.22 (dd, 
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J=4Hz, 2Hz, 1H), 7.14 (s, 1H), 6.76 (d, J=9Hz, 2H), 6.61 (d, J=9Hz, 2H), 6.12 (s, 2H), 4.43 
(s, 2H), 3.85 (s, 3H), 3.21 (t, J=8Hz, 4H), 2.83 (m, 4H); MS (DCI/NH3) m/e: 443 (M + H)+.   
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-N-(2-hydroxyethyl)-
piperazine (54) 
General procedures d & e from V (86%); white powder; mp 142-144 °C; 1H NMR (400.13 
MHz) δ 8.18 (d, J=4Hz, 1H), 7.85 (s, 1H), 7.76 (d, J=2Hz, 1H), 7.32(s, 1H), 7.16 (dd, J=4Hz, 
2Hz, 1H), 7.10 (s, 1H), 6.05 (s, 2H), 3.96 (s, 3H), 3.82 (s,2H), 3.70 (t, J=6Hz, 2H), 2.70 (m, 
8H), 2.61 (m, 2H); MS (DCI/NH3) m/e: 395 (M + H)+.   
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-(2-hydroxyethylethoxy)-
piperazine (55) 
General procedures d & e from V (78%); white powder; mp 145-147 °C; 1H NMR (400.13 
MHz) δ 8.10 (d, J=4Hz, 1H), 7.80 (s, 1H), 7.75 (d, J=2Hz, 1H), 7.46(s, 1H), 7.14 (dd, J=4Hz, 
2Hz, 1H), 7.09 (s, 1H), 6.05 (s, 2H), 3.96 (s, 3H), 3.89 (s,2H), 3.79 (t, J=6Hz, 2H), 3.61 (t, 
J=6Hz, 2H), 3.49 (t, J=6Hz, 2H), 3.12 (m, 8H), 2.87 (m, 2H); MS (DCI/NH3) m/e: 439 (M + 
H)+.    
N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-4-piperidineethanol (56) 
General procedures d & e from V (88%); white powder; mp 148-149 °C; 1H NMR (400.13 
MHz) δ 8.08 (d, J=4Hz, 1H), 7.90 (s, 1H), 7.81 (d, J=2Hz, 1H), 7.45 (s, 1H), 7.22 (dd, 
J=4Hz, 2Hz, 1H), 7.17 (s, 1H), 6.09 (s, 2H), 4.14 (s, 2H), 3.98 (s, 3H), 3.52 (t, J=6Hz, 2H), 
3.00 (m, 2H), 2.58 (m, 2H), 1.65 (m, 4H), 1.55 (m, 1H), 1.43 (m, 2H); MS (DCI/NH3) m/e: 
394 (M + H)+.   
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N-(2,3-Methylenedioxy-6-methoxy-phenanthr-9-ylmethyl)-4-piperidineethanol 
hydrochloride (56-HCl) 
White powder; mp 153-155 °C; 1H NMR (400.13 MHz) δ δ 8.07 (d, J=4Hz, 1H), 7.94 (s, 
1H), 7.83 (d, J=2Hz, 1H), 7.50 (s, 1H), 7.22 (dd, J= 4Hz, 2Hz, 1H), 7.15 (s, 1H), 6.10 (s, 2H), 
4.56 (s,2H), 3.98 (s, 3H), 3.56 (t, J=6Hz, 2H), 3.44 (m, 2H), 2.84 (m, 2H), 1.85 (m, 4H), 1.73 
(m, 1H), 1.45 (m, 2H); MS (DCI/NH3) m/e: 394 (M + H)+.  Anal. 
(C24H27O4N·1.0HCl·2.0H2O) C, H, N,  
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-L-4-piperidinecarboxylic 
acid (57) 
Similar procedure as 47 (77% for d, e & f); white powder; mp 183-185 °C; 1H NMR (400.13 
MHz) δ 8.05 (d, J=4Hz, 1H), 7.89 (d, J=2Hz, 1H), 7.81 (s, 1H), 7.52 (d, J=4Hz , 2H), 7.43 (s, 
1H), 7.40 (t, J=4Hz, 2H), 7.33 (m, 1H), 7.26 (dd, J=4Hz, 2Hz, 1H), 7.15 (s, 1H), 6.08 (s, 2H), 
5.26 (s, 2H), 3.92 (s, 2H), 2.89 (m, 1H), 2.36 (m, 4H), 1.83 (m, 4H); MS (DCI/NH3) m/e: 470 
(M + H)+.  
N-(2,3-Methylenedioxy-6-benzyloxy-phenanthr-9-ylmethyl)-L-4-piperidinemethanol 
(58) 
General procedure g from 57 (93%); white powder; mp 120-122 °C; 1H NMR (400.13 MHz) 
δ 8.25 (d, J=4Hz, 1H), 7.89 (d, J=2Hz, 1H), 7.84 (s, 1H), 7.51 (d, J=4Hz, 2H), 7.44 (t, J=4Hz, 
2H), 7.33 (m, 1H), 7.26 (dd, J=4Hz, 2Hz, 1H), 7.15 (s, 1H), 6.07 (s, 2H), 5.28 (s, 2H), 3.95 
(s, 2H), 3.47 (d, J=3Hz, 2H), 2.12 (m, 4H), 1.69 (m, 1H), 1.48 (m, 4H); MS (DCI/NH3) m/e: 
456 (M + H)+.  
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4.6.5 Cell Growth Inhibition Assay 
The sulforhodamine B assay was used according to the procedures developed and validated 
at NCI.6  The in vitro anticancer activities are expressed as EC50 values, which is the test 
compound concentration (µM) that reduced the cell number by 50% after 72-h of continuous 
treatment.  The values were interpolated from dose-response data.  Each test was performed 
in triplicate with variation less than 5%.  The ED50 values determined in each of independent 
tests varied less than 10%.  Compound stock solutions were prepared in DMSO with the final 
solvent concentration ≤1% DMSO (v/v), a concentration without effect on cell replication.  
The cells were cultured at 37 °C in RPMI-1640 supplemented with 25 mM N-2-
hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES), 2% (w/v) sodium bicarbonate, 
10% (v/v) fetal bovine serum, and 100 µg/mL kanamycin in a humidified atmosphere 
containing 5% CO2.   
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Table 4-1. Cytotoxicity of 6-Methoxy-9-Substituted PTBs. 
 
O
O
MeO
2
3
6
9
R
 
Compound R 
EC50 (µM)  
A549 
27* -NH(CH2)4COOH 1.3 
28* -NH(CH2)4CH2OH 0.27 
31* N
HOOC
 
2.1 
32* N
HOH2C
 
0.7 
33* N
HOOC
 
0.5 
34* N
HOH2C
 
0.16 
43 N
HOOC
 
5.2 
44 N
HOH2C
 
1.1 
45 -NH(CH2)5COOH 0.8 
46 -NH(CH2)5CH2OH 0.2 
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47 N COOH
 
0.23 
48 N CH2OH 
0.08 
49 -NH(CH2)10COOH 3.2 
50 -NH(CH2)10CH2OH 2.6 
51 
N N
Cl
 
NA 
52 N N Cl
 
65.2 
53 N N OH
 
0.22 
54 N N OH
 
0.63 
55 N N
O
OH
 
57.1 
56 N OH
 
0.15 
Emetine  0.04 
Doxorubicin  0.18 
Etoposide(VP-16)  1.4 
Antofine  0.008 
Vincristine  0.04 
* From Chapter III. 
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Table 4-2. Cytotoxicity of 6-Benzyloxy-9-Substituted PBTs. 
 
O
O
C6H5H2CO
2
3
6
9
R
 
 
Compound R 
EC50 (µM)  
A549 
20* N
HOOC
 
3.2 
21* N
HOH2C
 
1.3 
57 N COOH
 
2.1 
58 N CH2OH 
0.7 
* From Chapter III. 
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Table 4-3. Cytotoxicity of PBTs in different cancer cell lines. 
 
EC50 (µM) 
Compound 
A549 KB DU-145 ZR-751 KB-VIN 
34 0.2 0.12 0.21 0.1 0.16 
34-HCl 0.16 0.12 0.09 0.08 0.09 
45 0.5 0.33 0.67 0.54 0.83 
46 0.16 0.25 0.04 0.13 0.35 
46-HCl 0.13 0.23 0.07 0.08 0.16 
47 0.23 0.15 0.31 0.25 0.38 
48 0.08 0.24 0.03 0.03 0.09 
48-HCl 0.07 0.07 0.05 0.04 0.04 
53 0.22 0.13 0.15 0.18 0.34 
54 0.63 0.50 0.25 0.23 0.51 
56 0.15 0.42 0.15 0.03 0.50 
56-HCl 0.09 0.20 0.1 0.02 0.20 
Antofine 0.008 0.013 0.009 0.008 0.009 
Emetine 0.04 0.04 0.06 0.1 >2 
Doxorubicin  0.18 0.18 0.13 0.04 >4 
Etoposide (VP-16) 1.4 4.8 2.4 3.1 >10 
Vincristine 0.04 0.006 0.085 0.04 5.3 
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5 CHAPTER V.  QUANTITATIVE STRUCTURE-ACTIVITY 
RELATIONSHIP ANALYSIS OF PHENANTHRINE-BASED 
TYLOPHORINE DERIVATIVES (PBTS) USING K-
NEAREST NEIGHBOR AND DATABASE MINING 
 
 
5.1 INTRODUCTION 
In Chapters III and IV, we described a novel series of polar water-soluble phenanthrene-
based tylophorine derivatives (PBTs) with EC50 ≅10-7 M against the A549 human lung cancer 
cell line.  These compounds could possibly have lower or no CNS toxicity because the 
increased polarity should prevent them from penetrating the blood-brain barrier. The target(s) 
of PBTs function has not been identified; however, several structure-activity trends have 
been observed: 1) A planar phenanthrene system is required, but not sufficient for cytotoxic 
activity.  2) A N-hydrophilic substituent at the C-9 position is essential for the enhanced 
cytotoxicity and should be linked through a methylene rather than a carbonyl group.  3) This 
C-9 N-hydrophilic substituent is ideal for the introduction of a polar moiety.  Analogs 
containing terminal carboxylic acid or hydroxymethyl groups are more favorable than those 
with methyl esters.  4) On the phenanthrene skeleton, a methoxy substituent best fits both the 
steric and electronic requirements at the C-6 position and is preferred over benzyloxy and 
hydroxy groups.  5) Adding a methylenedioxy ring at the 2, 3 position of the planar 
phenanthrene system can dramatically enhance the cytotoxic activity and led to the most 
potent derivatives.  The new PBT derivatives possess a novel structure and showed 
remarkable EC50 values in the sub-micromolar range, comparable those of with front-line 
 
antineoplastic drugs, suggesting that this new compound class is of great potential to be 
developed into antitumor drugs.  Useful and powerful quantitative structure-activity 
relationship (SAR) would greatly facilitate such further development. 
Many different QSAR approaches, including both two-dimensional (2D) and three-
dimensional (3D) methods, have been developed during the past few decades.1-9  The major 
differences among these methods can be analyzed from two viewpoints: (i) structural 
parameters (descriptors) that are used to characterize molecules; (ii) the mathematical 
approach used to establish a correlation between biological activity and descriptor values.  In 
recent years, we have been motivated to explore possible alternatives that would use 
alignment-free descriptors derived from 2D molecular topology, which can alleviate the 
frequent ambiguity of structural alignment typical for 3D QSAR methods.  Consequently, our 
molecular modeling laboratory has developed a variable selection approach, k nearest 
neighbor (kNN) QSAR10, which employs topological descriptors of chemical structures. 
Variable selection techniques choose the most informative variables and eliminate irrelevant 
variables to improve the signal-to-noise ratio in the resulting models. Additionally, these 
techniques are not computationally intensive and are practically automated.  The validated 
2D_kNN models with high predictive power can be easily adapted to conduct a database 
search or virtual screening.11 This strategy was recently applied successfully to the discovery 
of novel anticonvulsant agents12-13 and D1 dopaminergic antagonists.14
In this chapter, we discuss the application of a kNN method on an experimental dataset 
including 52 PBTs with known EC50 values (Tables 5-1, 5-2, and 5-3).  Their structures were 
characterized with MolConnZ15 (MZ) descriptors.  The models developed herein have been 
extensively validated using several criteria of robustness and accuracy.16 The robustness of 
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the models was evaluated from the values of the internal leave-one-out cross-validated R2 
(q2) for the training sets and external R2 (predictive R2) for the test sets, as well as other 
criteria.  The developed models with high predictive power were adapted to mining the 
publicly available commercial ChemDiv17 database, and resulted in 34 consensus hits with 
moderate to high activities.  Ten structurally diverse hits were experimentally tested and 
eight compounds were confirmed active, with the most potent compound having an EC50 
value of 1.8 µM.  The predictive power of the models was further confirmed by the high 
correlation coefficient between the predicted and actual cytotoxic activity for an external set 
including four new PBTs and the eight active ChemDiv hits, which not included in the 
original 52 PBTs dataset.  The correlation coefficient (R2) was as high as 0.52. This result 
demonstrated a successful application of modern QSAR to traditional medicinal chemistry 
research. 
5.2 DATASET AND BIOLOGICAL ACTIVITY  
All PBTs used in this study were synthesized and evaluated (Tables 5-1, 5-2, 5-3) as 
described in Chapters III and IV.  The general synthetic procedures and the biological, 
physical and spectral data were reported therein.  The identified hits via database mining hits 
were purchased from Chem.Div, Inc with physical and spectral data.  The human A549 lung 
cancer cell line was used for the cytotoxicity screening of PBTs and ChemDiv consensus hits 
using the cell-based sulforhodamine B (SRB) microtitre plate assay18,which has been 
reported in detail elsewhere. 
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5.3 COMPUTATIONAL METHODS 
5.3.1 Generation of Molecular Descriptors 
All chemical structures were generated using SYBYL 7.0.19 Molecular descriptors20 
were calculated for each compound with the MolConnZ (MZ) software version 4.05.15  
Overall, MolConnZ produces over 400 descriptors.  In our study, only 244 chemically 
relevant descriptors were used after removing those with zero values or zero variance prior to 
model generation.  MZ descriptors were range-scaled prior to distance calculations because 
the absolute scales for MZ descriptors can differ by orders of magnitude.  Using range 
scaling could avoid disproportional weightings upon distance calculations in 
multidimensional MZ descriptor space.  
5.3.2 Dataset Division into Training and Test Sets 
It is generally accepted that the internal validation of the QSAR models built for the training 
set is sufficient to establish their predictive power.21-30  However, our previous studies as well 
as those conducted by other groups have demonstrated that no correlation exists between 
leave-one-out (LOO) cross-validated R2 (q2) for the training set and the correlation 
coefficient R2 between the predicted and observed activities for the test set.16,31  We have 
developed a rational approach to dividing the dataset into multiple training and test sets for 
internal and external validations.32  
 
The dataset of 52 compounds was divided into multiple chemically diverse training and test 
sets with the algorithm based on Sphere Exclusion (SE) developed in our group.32  SE is a 
general procedure that is typically applied to databases of organic molecules characterized by 
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multiple descriptors of their chemical structure such that each compound is represented as a 
point (or vector) in multidimensional descriptor space.  The goal of the SE method is to 
divide a dataset (i.e., a collection of points in multidimensional chemometric space) into two 
subsets (training and test set) using a diversity sampling procedure as follows.  SE starts with 
the calculation of the distance matrix D between representative points in the descriptor space.  
Let Dmin and Dmax be the minimum and maximum elements of D, respectively.  N probe 
sphere radii are defined by the following formulas.  Rmin=R1=Dmin, Rmax=RN=Dmax/4, 
Ri=R1+(i-1)*(RN-R1)/(N-1), where i=2,…,N-1.  Each probe sphere radius corresponds to 
one division into the training and test set.   
In this study, each compound was characterized with multiple MolConnZ descriptors.  
The entire dataset was then treated as a collection of points (each corresponding to an 
individual compound) in the MolConnZ descriptor space.  Thus, the SE algorithm used in 
this study consisted of the following steps.  (i) Select randomly a point in the MolConnZ 
descriptor space.  (ii) Include it in the training set.  (iii) Construct a probe sphere around this 
point.  (iv) Select points from this sphere and include them alternatively into test and training 
sets. (v) Exclude all points within this sphere from further consideration.  (vi) If no more 
compounds left, stop.  Otherwise let m be the number of probe spheres constructed and n be 
the number of remaining points. Let dij (i=1,…,m; j=1,…,n) be the distances between the 
remaining points and probe sphere centers. Select a point corresponding to the lowest dij 
value and go to step (ii).  The training sets were used to build models and the test sets were 
used for validation. 
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5.3.3 kNN QSAR Method 
Our kNN QSAR method10 employs the kNN pattern recognition principle33 and a 
variable selection procedure.  Briefly, a subset of nvar (number of selected variables) 
descriptors between 1 and the total number of the original descriptors is selected randomly as 
a hypothetical descriptor pharmacophore (HDP).  The model is built using this random 
descriptor selection with leave-one-out (LOO) cross-validation, where each compound is 
eliminated from the training set and its biological activity is predicted as the average activity 
of k most similar molecules (k = 1-5).  The value k is optimized during the model building 
process to give the best prediction of the training set.  The similarity is characterized by the 
Euclidean distance between compounds in multidimensional descriptor space.  A method of 
simulated annealing with the Metropolis-like acceptance criterion is used to sample the entire 
descriptor space to converge on the subset of the same size that affords the highest value of 
LOO R2 (q2).  The descriptor subsets of different sizes are optimized using this procedure to 
arrive at a variety of models with acceptable q2 greater than a certain threshold (we chose 0.6 
as the default threshold).  The training set models with acceptable q2 are then validated on 
external test sets to select predictive models as discussed above.  Further details of the kNN 
method implementation, including the description of the simulated annealing procedure used 
for stochastic sampling of the descriptor space, are given elsewhere.10
The original kNN method10 was enhanced in this study by using weighted molecular 
similarity.  Estimated activities ŷi of compounds excluded by LOO procedure are calculated 
using the following formulas. 
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and dij are the distances between compound i and its k nearest neighbors. After each run, 
cross-validated R2 (q2) is calculated. 
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where yi, and y  are the actual and average values of activity. The summation in (3) is 
performed over all compounds.  
In summary, the kNN QSAR algorithm generates both an optimum k value and an 
optimal nvar subset of descriptors, which afford a QSAR model with the highest value of q2.  
Figure 5-1 shows the overall flowchart of the current implementation of the kNN method. 
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Training set with original descriptors and activity
Randomly select a subset of descriptors (a hypothetical 
descriptor pharmacophore)
Leave out a compound
Find k nearest neighbors in the training set
Predict the activity of the eliminated compound as the 
weighted average affinity of its k nearest neighbors.
Calculate the cross-validated q2 of the model
N
 tim
es
Sim
ulate A
nnealing
Select acceptable models with q2 > 0.6
N
 tim
es
Sim
ulate A
nnealing
 
Figure 5-1. Flowchart of the kNN method. 
 
5.3.4 Robustness and predictive power of QSAR Models (Y-Randomization Test) 
The robustness of the models was examined by comparing them to those obtained when 
using randomized activity of the training set (this procedure is commonly referred to as the 
Y-randomization test).  Briefly, we repeated the QSAR calculations with the randomized 
activities of the training sets.  We also compared the q2 values in the process of the iteration 
procedure of the simulating annealing for actual and random activities of training sets to see 
if there was any significant difference.  This randomization was repeated five times for each 
splitting.  This technique is widely used to ensure the robustness of a QSAR model.34  It is 
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expected that the resulting QSAR models should generally have low training set fitness q2 
and low test set R2.  It is likely that sometimes, though infrequently, high training set 
statistics may be obtained due to a chance correlation or structural redundancy of the training 
set.35  If all QSAR models obtained in the Y-randomization test exhibit relatively high 
training set statistics and test set R2 values, it implies that an acceptable QSAR model cannot 
be obtained for the given dataset by the current modeling method.  This test was applied to 
all data splits considered in this study. 
To estimate the predictive power of a QSAR model, the following criteria were used:16 
(i) correlation coefficient R between the predicted and observed activities; (ii) coefficients of 
determination (predicted versus observed activities , and observed versus predicted 
activities ); (iii) slopes k and k' of regression lines (predicted versus observed activities, 
and observed versus predicted activities) through the origin.  We conclude that a QSAR 
model has an acceptable predictive power if the following conditions are satisfied:
2
0R
2
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R2>0.6;        (5) 
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15.185.0 ≤≤ k  or 15.1'85.0 ≤≤ k .      (7) 
Earlier, we suggested16 that preferably both values of  and  must satisfy condition 
(6).  This condition appears to be too strong; thus, herein we employed a less stringent 
condition: we have required that the difference between and  should not be too high as 
follows: 
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 5.3.5 Applicability Domain of kNN QSAR Models.  
Formally, a QSAR model can predict the target property for any compound for which 
chemical descriptors can be calculated.  Since the training set models are developed in the 
kNN QSAR approach by interpolating activities of the nearest neighbor compounds,10 a 
special applicability domain (i.e., similarity threshold) should be introduced to avoid making 
predictions for compounds that differ substantially from the training set molecules.35  
To measure similarity, each compound is represented by a point in the M-dimensional 
descriptor space (where M is the total number of descriptors in the descriptor pharmacophore) 
with the coordinates Xi1, Xi2, ..., XiM, where Xis are the values of individual descriptors.  The 
molecular similarity between any two molecules is characterized by the Euclidean distance 
between their representative points.  Compounds with the smallest distance between one 
another are considered to have the highest similarity.  The distances (similarity) of 
compounds in our training set are compiled to produce an applicability domain threshold, DT, 
calculated as follows: 
D=<d>+Zσ     (9) 
where <d> is the average of Euclidean distances between k nearest neighbors of all points of 
the training set used in model derivation, σ is the standard deviation of these distances, and Z 
is the empirical parameter to control the significance level.  
Based on successful results from previous studies, we set the default value of this 
parameter to 0.5, which formally places the boundary for which compounds will be predicted 
at one-half of the standard deviation (assuming a Boltzmann distribution of distances 
between k nearest neighbor compounds in the training set).  Thus, if the distance of the 
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external compound from at least one of its nearest neighbors in the training set exceeds this 
threshold, the prediction is considered unreliable. 
5.3.6 Database Mining 
A commercially available chemical database, Chemical Diversity (ChemDiv17), which is 
a small compound collection database containing ca. 500,000 compounds, was screened.  MZ 
descriptors were generated for each compound in the database and linearly normalized based 
on the maximum and minimum values of each descriptor in the training set.14   
The ten best kNN models were then used to predict activity for the database compounds 
that were within the applicability domain for that model.  The results for each individual 
prediction exercise were then combined, and the mean predicted activity was calculated for 
each compound that was within the applicability domain of multiple models.  The percentage 
of models that predicted each compound in the database and the standard deviation of those 
predictions were also recorded for each compound.  We hypothesized that the higher the 
percentage of models with a stringent applicability domain that predict a compound's activity, 
the more likely the compound actually possesses the predicted activity.  This postulate may 
also apply to the standard deviation of the predictions made for a single compound.  The 
smaller the prediction variance across all models, the more confidence we have that the 
predicted biological activity for that compound is accurate.  For these reasons, we selected a 
subset of compounds as hits that were predicted by at least 50% of the models and exhibited 
a small standard deviation across all models.  We also performed an additional estimate as to 
whether the hits resulting from database mining using variable selection models possessed 
the features essential (i.e., common) for all PBTs.  This additional precaution was considered 
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essential because variable selection procedure by default eliminates features (descriptors) that 
have the same values for all modeled compounds.   
5.4 RESULTS AND DISCUSSION 
5.4.1 QSAR models and Their Robustness 
In the kNN QSAR method, nvar can be set to any value that is less than the total number 
of descriptors.  Since the optimal number for nvar is not known a priori, multiple models 
must be generated to examine the relationship between q2 and nvar.  As previously discussed, 
the robustness of a QSAR model should be established by comparing results for the actual 
data set with those for data sets with randomized activity values.  Thus, 10, 20, 30, 40 and 50 
descriptor models were generated.  Figure 5-2 shows a plot of q2 vs nvar for the actual and 
random data sets obtained with kNN calculations.  Every q2 value is the average of 10 
independent computations.  Overall, we obtained consistently much higher q2 values for the 
actual data set compared to those from Y-randomization.  The q2 values for the real data set 
were in the range 0.60 to 0.70 compared to -0.10 to 0.10 for the random data sets. 
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Figure 5-2. Plots of q2 versus the number of descriptors selected for the best kNN 
QSAR models for 52 PBTs. The results for both actual and random (with shuffled 
activity values) data sets are shown. Every q2 value is the average of 10 
independent calculations. Circles represent the actual data set, and triangles 
represent the random data set. 
 
5.4.2 kNN QSAR Model Validation 
Generally, we accept models with q2 values for the training set greater than 0.5 and R2 
values for predicted vs actual activities of the test set compounds greater than 0.6.16  Table 5-
4 presents the ten best models obtained from multiple kNN analyses.  In order to obtain 
statistical significance, the original 52-compound dataset was divided into 50 training and 
test sets.  Multiple variable selection models with the highest q2 values (greater than 0.5) 
were collected.  However, as indicated in one of our earlier studies,16 no correlation was 
found between q2 and R2, also shown in Figure 5-3, demonstrating that q2 alone does not 
serve as an estimate of the predictive power of kNN models.  On the basis of our criteria, 
acceptable models with both high statistical significance (q2 > 0.5) and predictive power (R2 
> 0.6) represented only a fraction of all models with q2 > 0.5 (Figure 3).  So the 
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aforementioned conditions (Equations 4–8) become very important.  Based on all of these 
criteria, the best models were obtained for the test sets including 14 and 18 compounds, with 
the optimal number of descriptors as 15 and 20, respectively (Table 5-4).  Figure 5-4 shows 
actual vs. calculated activity correlations for the training and test sets with q2 = 0.59 and R2 = 
0.81 respectively.  Two outlying points {compound 20 and 54 antofine)] were poorly 
predicted.  The latter point represents antofine, a positional isomer of tylophorine isolated 
from Asclepiadaceae by Dr. T. S. Wu36 in Taiwan; its structure is shown in Table 5-3.  It was 
used as a reference compound when we screened PBTs.  A possible explanation for this 
observation is that this compound lacks the chemical structure descriptors that are most 
meaningful and statistically significant in terms of correlation with biological activity: a N-
hydrophilic substituent and free rotating C-9 methylene bond, which were proven to be 
required for PBT analog activity in our preliminary study.  Mechanism of action studies for 
antofine and PBTs are still ongoing and it remains possible that they have different modes of 
action.  In regard to compound 20, its terminal Cl group may cause some solubility or cell 
membrane transportation problem that would result in diminished activity in our cell-based 
assay. 
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Figure 5-3. R2 versus q2 for all selected models with q2>0.5. Triangles for 
models with R2<0.6 and open circles for models with R2>0.6 
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Figure 5-4. Plot of Actual versus Predicted activity for one of the best 10 
models. This model has 18 compounds in the test set, and correspondingly, 34 
in the training set. Twenty descriptors have been selected for the calculation. 
q2=0.59 and R2=0.81 
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 .4.3 Interpreting predictive QSAR models   
ptors, a number of MolConnZ descriptors 
w
5
Upon the frequency analysis of selected descri
ere identified suggesting that they played critical roles in relating chemical structures to 
their antitumor activity.  These descriptors include molecular connectivity descriptors such as 
Chi indices, hydrogen bond counts and E-state descriptors, atom type E-state descriptors, 
shape indices, etc.  These results are consistent with our preliminary SAR observations, as 
described in the Introduction to this chapter.  Based on the MolConnZ manual and personal 
communication with Dr. Lowell Hall, one of the principle MolConnZ developers, these 
selected descriptors have been grouped into the following classes: 1) The high frequency of 
the Chi indices, including dXvp7, dXvp10, nXp6, Xvp7, etc., suggests the importance of 
those structure features such as size, branching, and cyclicity.  Our previous SAR study 
showed that both para-positioned functional groups and three intra-atomic distances are very 
important to the antitumor activity.  These features define the relative spatial dispositions of 
three significant atoms: the oxygen of C-9 chain terminal, the nitrogen atom, and a methoxy 
oxygen on the phenanthrene ring.  2) Hydrogen bond donors/acceptors counts and E-states 
descriptors, such as nHBint9, SHBd, Hmax, Hmin, indicate the importance of polar hydrogen 
atoms and hydrogen bond interactions during binding.  This observation agrees with the 
finding that the presence of a hydrogen bond acceptor/donor group at the C-9 chain terminus 
appears essential for cytotoxic activity and analogs containing terminal carboxylic acid or 
hydroxymethyl groups are more favorable than those with methyl esters.  3) The appearance 
of atom type counts and E-states descriptors (SssCH2, nsssCH, and SsOH) demonstrated a 
high importance of electron accessibility for those atoms.  Our studies indeed found that an 
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N-hydrophilic substituent at the C-9 position is essential for enhanced cytotoxicity and 
should be linked through a methylene rather than a carbonyl group.  4) Several steric 
crowding related descriptors (n2Pag12 and Tm) occurred many times in our models.  This 
point is reflected in our finding that a methoxy substituent best fits both the steric and 
electronic requirements at the C-6 position.  5) Several Kappa and complexity indices (ka1, 
ka2, tets1, tets2, graphcomplexity, etc.) were found in many models, suggesting that shape 
related features are important for the cytotoxicity in our PBTs.  It was noted that a planar 
phenanthrene system is required, although not sufficient, for the cytotoxic activity.  Also 
adding a methylenedioxy ring at the 2, 3 positions of the planar phenanthrene system can 
dramatically enhance the cytotoxic activity and leads to the most potent derivatives.  6) Last, 
not least, descriptors such as nCl and SsCl indicate the importance of a Cl atom to the 
activity.  Several structures with Cl (e.g., compounds 64 and 68) showed high activity (EC50 
as low as 1.8 µM) when their activities were not hindered by solubility in the biological 
assay. 
5.4.4 Database mining with predictive QSAR models 
compounds, was screened with 
our 
se 
 
ChemDiv., a small compound collection of ca. 500,000 
ten best QSAR models within a defined applicability domain, and predicted activities 
were averaged to yield consensus values.  Thirty-four consensus hits were identified with 
moderate to high predicted activities.  Among them, some compounds shared very similar 
core chemical structures, while some were very different.  Eventually, ten structurally diver
hits (59-68, Table 5-5) with moderate to high predicted activity were chosen, purchased and 
screened using the same cell line and assay method as for the PBT screening.  The chemical 
structures and experimental biological data are shown in Table 5-5.  Eight (59, 61-62, 64-68)
 88  
of the ten compounds were confirmed to be active against the A549 lung cancer cell line, and 
compound 68 (ChemDiv #: K915-0700) showed the best activity with an EC50 of 1.8 µM, 
comparable to the active PBTs.  This hit (68) has similar activity, but a novel core structure
different from either known PBTs or anticancer drugs.  Since all compounds in the ChemDiv
database were synthesized automatically by combinatorial chemistry and no biological data 
were annotated, our screening provides the first associated anticancer activity for these novel
structures.  
Althoug
 
 
 
h the prediction accuracy for the screening hits was lower than for the original 
cong  
5.4.5 Prediction of Anticancer Activity for an External Data Set 
 demonstrate that the 
train
d activity that ranged 
betw
eneric (core structure similar) compound set (see explanation in the next paragraph), the
high experimental hit rate and capability of detecting novel active structures from a large 
chemical database confirm this method as a very useful and powerful tool in drug lead 
identification.  
As a reliable and truly predictive QSAR model, it is necessary to
ing set models can accurately predict activities of new compounds in external test sets.  
To this end, the kNN QSAR models validated with the test sets were used to predict the 
activity of four new compounds (Table 5-5), which were not available prior to our QSAR 
studies of the 52-compound PBT dataset.  Concurrently, the eight active hits (Table 5-6) 
from ChemDiv, which had moderate to high predicted activities, were also used to evaluate 
the accuracy of prediction using our models in a quantitative manner.   
All of the external compounds displayed moderate to high predicte
een 0.15 and 72.4 µM (Tables 5-5 & -6), while the original training set compounds 
(Tables 5-1, -2 & -3) featured EC50 activity values that ranged between 0.08 and 80 µM log 
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EC50 units.  Tables 5-5 & -6 list the averaged predicted activity values for the external data 
set obtained from the best kNN models.  We intentionally selected a series of compounds that 
have a wide range of predicted activity, paralleling those used in the training and test sets 
during the model building.  This choice will help us to confirm the predictive power of our 
models in a wider applicability domain.  The obtained correlation coefficient R2 was as high 
as 0.57 (Figure 5-5).  It was interesting to analyze the performance of QSAR models with 
respect to the congeneric (core structure similar) compounds and novel (core structure 
different) compounds.  With the four congeneric PBTs, the difference in absolute value 
between the predicted activity and experimental was less than 0.2 for compounds 55, 56 and 
58 and 0.6 for compound 57.  For the eight structurally diverse hits set (Table 5-6), the 
models performed slightly worse than for the congeneric compounds.  Two reasons can be 
suggested and discussed as follows.  1) The congeneric and the novel hit compounds have 
high structural dissimilarity.  The models are based on the structure-activity data of the 
training set (congeneric), so the selected descriptors are not sufficient to reliably and 
accurately predict the activity of external diverse (novel) structures.  This problem always 
exists in statistical modeling, and the final result could be improved by using more 
descriptors.  2) Since this is a whole cell based assay, activity may be hindered by poor 
physicochemical properties (solubility, cell membrane transportation, stability, etc.) or 
metabolic problems, which lead to lower actual activity than predicted in most of the cases.  
(Compound 68 was an exception; the actual activity was higher than the predicted activity.)  
Fortunately, the high correlation coefficient (R2=0.57) demonstrates that our QSAR models 
are still very robust and predictive for most of both congeneric and novel compound 
structures and could be used to diversify the chemical repertoire of anticancer agents.  
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Figure 5-5. Plot of actual versus predicted activity for the screened and the 
designed compounds. Compounds 60 and 63 were inactive experimentally, so 
12 out of 14 compounds were included with consensus prediction based on the 
10 best models. R2 = 0.57. 
 
 
.5 CONCLUSIONS 
Since 1971, our Natural Products Lab at UNC-CH has discovered more than 1,000 new 
nd their synthetic derivatives.  Among them are many anticancer 
com
ning.  
 
5
bioactive natural products a
pounds, 100 of which have been chosen by the National Cancer Institute for evaluation.  
As part of these studies in plant-derived antitumor agents, we initiated the design and 
synthesis of new tylophorine analogs, because of their profound anticancer activity.  These 
PBTs were newly discovered and developed in our laboratory.  The structure of this 
compound class is still being optimized and a mechanism of action study is in progress.  
Herein, we report our recent lead optimization using QSAR analysis and database mi
We developed and thoroughly validated QSAR models for a series of PBT derivatives.  In
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agreement with our expectation, the result showed that this approach could efficiently and 
successfully generate multiple models with high internal and external accuracy, and these 
models have been further exploited in database mining for new lead structures.  Their high 
predictive ability allowed the successful virtual screening of a large chemical database with
an exceptional high hit rate (80%).  Those hits (68) lacking a phenanthrine ring but having 
high activity (EC
 
 
 
50=1.8 uM) may in fact lead to a novel structural class of anticancer agents. 
We believe that this approach should facilitate the design of new natural product analogs as
well as the search for new structures with anticancer activity from large chemical databases.  
On the basis of the current QSAR results and earlier practical SAR trend analysis, a more 
detailed “pharmacophore” model may be constructed for guiding the further design of new 
analogs in the future. 
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Table 5-1. Structure and cytotoxic activity of PBTs (3-40) used in model building. 
R2
R1O
O
O 2
3
6
9
 
Compound R1 R2 EC50  (µM)a,b
3 -CH3 -CONH(CH2)4COOH 73.3 
4 -CH3 -CH2NH(CH2)4COOMe 25.3 
5 -CH3 -CH2NH(CH2)4COOH 1.3 
6 -CH3
-CH2NH(CH2)4CH2OH 0.27 
7 -CH3
-CONH(CH2)5COOH 27 
8 -CH3 - CH2NH(CH2)5COOMe 18 
9 -CH3 - CH2NH(CH2)5COOH 0.8 
10 -CH3 - CH2NH(CH2)5CH2OH 
0.2 
11 -CH3 N
O
HOOC
 
5.3 
12 -CH3 N
MeOOC
 
73.8 
13 -CH3 N
HOOC
 
2.1 
14 -CH3 N
HO
 
0.7 
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15 -CH3 N
HOOC
 
0.5 
16 -CH3 N
HO
 
0.16 
17 -CH3 N COOH 
0.23 
18 -CH3
N CH2OH 
0.08 
19 -CH3 N N
Cl
 
33.8 
20 -CH3
N N Cl
 
65.2 
21 -CH3 - CH2NH(CH2)10COOH 3.2 
22 -CH3
- CH2NH(CH2)10CH2OH 2.6 
23 -CH2C6H5 -CONH(CH2)5COOMe 41.2 
24 -CH2C6H5 -CONH(CH2)5COOH 41.2 
25 -CH2C6H5 -CH2NH(CH2)5COOH 1.6 
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26 -CH2C6H5 -CH2NH(CH2)5CH2OH 1.1 
27 -CH2C6H5 -CH2NH(CH2)4COOMe 17.0 
28 -CH2C6H5 -CH2NH(CH2)4COOH 2.2 
29 -CH2C6H5 N
O
HOOC
 
42.6 
30 -CH2C6H5 N
MeOOC
 
32.1 
31 -CH2C6H5 N
HOOC
 
4.4 
32 -CH2C6H5 N
HO
 
1.8 
33 -CH2C6H5 N
HOOC
 
3.2 
34 -CH2C6H5 N
HO
 
1.3 
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35 -CH2C6H5 -CONH(CH2)5COOMe 41.2 
36 -CH2C6H5 -CONH(CH2)5COOH 41.2 
37 -CH2C6H5 -CH2NH(CH2)5COOH 1.6 
38 -H N
O
HOOC
 
39.7 
39 -H 
N
HOOC
 
41.2 
40 -H N
HOOC
 
39.7 
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Table 5-2. Structure and cytotoxic activity of  PBTs (41-48) used in model building. 
R
H3CO
OCH3
H3CO 2
3
6
9
 
Compound R EC50  (µM) 
41 -NH(CH2)10COOH 13.0 
42 -NH(CH2)10CH2OH 3.6 
43 -CH2NH(CH2)5COOH 9.7 
44 -CH2NH(CH2)5CH2OH 2.7 
45 N
HOOC
 
9.7 
46 
N
HO
 
6.3 
47 N COOH
 
19.2 
48 N CH2OH 2.4 
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Table 5-3. Structure and cytotoxic activity of PBTs (49-54) used in model building. 
 
Compound Structure EC50  (µM) 
49 
MeO
MeO OMe
N
NO2
O
HOOC
 
80 
50 
MeO
MeO OMe
N
NO2
HOOC
 
45.2 
51 
MeO
MeO OMe
N
NO2
HO
 
11.7 
52 
MeO
MeO OMe
NHO
 
52.2 
53 
H3CO
OCH3
H3CO
OCH3
N
HN
H
H
H
H
 
0.02 
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54 
N
OMe
MeO
MeO  
0.008 
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Table 5-4. Ten best kNN QSAR models. 
 
Models Test Sets Training Sets Number of Descriptors q
2 R2
1 8 44 15 0.52 0.75 
2 11 41 20 0.53 0.8 
3 12 40 10 0.72 0.71 
4 12 40 15 0.72 0.72 
5 14 38 10 0.56 0.77 
6 14 38 20 0.51 0.81 
7 14 38 15 0.58 0.81 
8 14 38 15 0.54 0.79 
9 18 34 20 0.59 0.81 
10 20 32 15 0.55 0.73 
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Table 5-5. Structure and cytotoxic activity for compounds (59-68) from ChemDiv.  
 
No Structure 
 
ChemDiv 
ID # 
Actual 
Activity 
EC50, uM 
Actual 
Activity 
-logEC50
Predicted 
Activity 
-logEC50
59 
N
OH
O
 
1661-1313 10.9 4.959164 5.8601 
60 O
O
O
O
OH
O
O  
2188-3298 N/A N/A 4.993 
61 Cl N N
H
N OH
O
 
3253-1073 19.3 4.714376 4.521778 
62 
O
O
O
N
OH
N
O
O  
3346-2033 42.6 4.370451 4.4711 
63 O
N
N
N
HO O
 
3570-0022 N/A N/A 5.7561 
64 N N N
Cl
OH
 
4106-0061 7.9 5.104735 5.8307 
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65 
N
H
N
OH
 
6658-0014 11.1 4.955545 6.5566 
66 N N NHO
OMe
OMe
OMe
 
C614-0150 17.3 4.763018 4.969401 
67 
N N NO2
N
O
N
OO
NH
OH 
K901-0689 72.4 4.140272 5.0105 
68 
O
O
N
N
H
O
OH
Cl  
K915-0700 1.8 5.737391 5.210599 
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Table 5-6. Structure and cytotoxic activity for PBTs (55-58) in external set. 
 
O
O
MeO
2
3
6
9
R
 
Compound R 
Actual 
Activity 
 (EC50, uM) 
Actual 
Activity 
 (-logEC50) 
Predicted 
Activity 
(-logEC50) 
55 N N OH
 
0.22 6.645422 6.807934 
56 N N OH
 
0.63 6.197556 6.808 
57 N N
O
OH
 
57.1 4.243534 4.416317 
58 N OH
 
0.15 6.816241 6.604551 
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6 CHAPTER VI.  ADME EVALUATION AND  
MODE OF ACTION STUDY 
 
 
ADME EVALUATION 
6.1 INTRODUCTION 
Compound toxicity plays a key role in determining success in drug development,* and 
50% of drug failures are attributed to ADME-Tox issues.  Thus, it is critical to accurately 
predict these properties earlier in the investigation of a lead to assure appropriate selection in 
the drug development process.  New prediction techniques and technologies are making it 
possible to more quickly eliminate compounds that are most likely to exhibit ADME or 
toxicity problems, and provide ways for researchers to still arrive at correct conclusions, but 
in less time.  The more attractive compounds can then be put on the development fast track, 
saving time and money.  Therefore, an ADME prediction program 
(http://preadme.bmdrc.org), which uses an artificial neural network with back-propagation 
method, was used to predict blood brain barrier (BBB) permeability, human intestinal 
absorption (HIA) and protein binding percentage of PBTs that hold promise for improving 
the selection of potent, on-target leads with fewer negative side-effects. 
                                                 
* As we mentioned earlier, in the early 1960s drug development of tylocrebrine was terminated due to its 
significant CNS toxicity manifested as disorientation and ataxia1.   
 
6.2 METHODOLOGY 
6.2.1 Prediction of CNS Toxicity 
An ADME prediction model (http://preadme.bmdrc.org), which uses an artificial neural 
network with back-propagation method, was used to predict the BBB permeability of 
selected compounds in comparison with their parent tylophora alkaloids.  This model 
contains over 15,000 CNS active compounds and 50,000 CNS inactive compounds, and each 
molecule is describable by 7 1D descriptors and 166 2D descriptors.  This model was 
validated by a database of 275 known CNS active compounds.  The accuracy of the 
prediction was 92%.  Therefore, it is a reliable filter to screen potential candidate compounds 
for CNS toxicity.2
6.2.2 Prediction of Human Intestinal Absorption3-4 and Plasma Protein Binding5 
An ADME prediction model (the same as above) was also used to predict the human 
intestinal absorption and plasma protein binding of selected compounds in comparison with 
their parent tylophora alkaloids. 
6.2.3 Results and Discussion 
The predicted ADME values of four PBTs (1-4) and three parent tylophora alkloids are 
shown in Table 6-1.  Preliminary data indicated that all PBT compounds should be well 
absorbed in the human intestine (HIA ≥92.5%). In addition, the four PBTs showed lower 
predicted brain/blood concentration ratios (Cbrain/Cblood = 1) than the tylophora alkloids, 
indicating that less PBT compound would penetrate the blood brain barrier (BBB) and, thus, 
the probability of CNS toxicity would be low.  In contrast, the high predicted ratio (8.3) of 
tylocrebrine indicated a high probability of compound BBB entry, which would readily 
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explain its clinical CNS toxicity.  In addition, the PBTs were predicted to have higher protein 
bound constants (76%-90%) than the tylophora alkaloids (74%-78%).  This parameter is a 
favorable pharmacokinetic property for drug development. In summary, PBTs have better 
predicted ADME profiles than tylophora alkaloids in our preADME screen.    
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Figure 6-1. Structure of tylophora alkloids and PBTs (1-4) selected for ADME prediction. 
 
 
 
Table 6-1. ADME predictions of human intestinal absorption, blood brain barrier penetration, 
and protein binding of PBT compounds vs tylophora alkaloids. 
 
Compound BBB permeability (Cbrain/Cblood) 
HIA (%) Plasma Protein Binding (%) 
Tylophora Alkaloids 
Antofine 11.7 94.2 74.9 
Tyloindicine F 4.5 91.7 77.9 
Tylocrebrine 8.3 93.9 74.0 
PBTs 
1. 0.61 93.6 85.7 
2. 1.0 93.8 89.8 
3. 2.7 92.5 84.4 
4. 1.6 93.5 75.7 
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MODE OF ACTION STUDY 
6.3 INTRODUCTION 
Prior evaluation of (+)-(S)-tylophorine and its analogs in the antitumor screen at the 
National Cancer Institute showed a uniform and potent inhibitory effect on cancer cell 
growth (GI50 ≈ 10-8 M) in all 60 cell lines with notable selectivity toward several refractory 
cell lines including melanoma and lung tumor cell lines.6  Earlier studies in the 1960s 
demonstrated that the mechanism of antitumor activity of tylophorine alkaloids was to 
irreversibly inhibit protein synthesis at the elongation stage of translation.7-11  However, 
comprehensive evaluation of antitumor potential has not been reported, and the mechanisms 
of cell growth inhibition are largely unknown.  In the 1990s, several key regulators of 
signaling transduction were reported as the biological targets of tylophorine alkaloids 
including thymidylate synthase (TS)12,13 and dihydrofolate reductase.14  In addition, these 
compounds were also found to induce cell apoptosis.15  Most recently, Gao et al.16 
demonstrated that the tylophorine analogs have significant inhibitory effects on NF-kB 
mediated transcription.  These recent discoveries emphasize the great potential of developing 
tylophorine derivatives into a new antitumor drug class with a unique mode of action.  In this 
study, we have reported the discovery of novel phenanthrene-based tylophorine (PBT) 
derivatives with profound inhibition against several human cancer cell lines.  However, the 
biological target of this class of novel compounds has not been identified.  Further screening 
against more cancer-related cell lines will facilitate our understanding of the specific targets 
of this new compound class and provide insight into definitive structure-activity relationships. 
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Selected interesting compounds were sent for additional screening at collaborative 
laboratories, including NCI-DTP, MD Anderson Cancer Center, Dr. M. Jarstfer’s Laboratory 
at UNC-CH, and MDS Pharma Services -Taiwan Ltd.  The major findings of these screens 
are given below.   
6.4 NCI-DTP HUMAN TUMOR CELL LINES SCREENING (17-19): 
The In Vitro Cell Line Screening Project (IVCLSP) is a dedicated service providing 
direct support to the DTP anticancer drug discovery program.  This project utilizes 59 
different human tumor cell lines, representing leukemia, melanoma and cancers of the lung, 
colon, brain, ovary, breast, prostate, and kidney.  The aim is to prioritize synthetic 
compounds or natural product samples, which show selective growth inhibition or cell killing 
of particular tumor cell lines, for further evaluation.  This screen is unique in that the 
complexity of a 59 cell line dose response produced by a given compound results in a 
biological response pattern that can be utilized in pattern recognition algorithms.  Using these 
algorithms, it is possible to assign a putative mechanism of action to a test compound, or to 
determine that the response pattern is unique and not similar to that of any of the standard 
prototype compounds included in the NCI database.  In addition, following characterization 
of various cellular molecular targets in the 59 cell lines, it may be possible to select 
compounds most likely to interact with a specific molecular target.  
6.4.1 Methodology of the In Vitro Cancer Screen  
The human tumor cell lines of the cancer screening panel are grown in RPMI 1640 
medium containing 5% fetal bovine serum and 2 mM L-glutamine.  For a typical screening 
experiment, cells are inoculated into 96 well microtiter plates in 100 µL at plating densities 
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ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell 
lines.  After cell inoculation, the microtiter plates are incubated at 37° C, 5 % CO2, 95 % air 
and 100 % relative humidity for 24 h prior to addition of experimental drugs.  
After 24 h, two plates of each cell line are fixed in situ with TCA, to represent a 
measurement of the cell population for each cell line at the time of drug addition (Tz).  
Experimental drugs are solubilized in dimethyl sulfoxide at 400-fold the desired final 
maximum test concentration and stored frozen prior to use.  At the time of drug addition, an 
aliquot of frozen concentrate is thawed and diluted to twice the desired final maximum test 
concentration with complete medium containing 50 µg/ml gentamicin.  Four additional 10-
fold or ½ log serial dilutions are made to provide a total of five drug concentrations plus 
control.  Aliquots of 100 µl of these different drug dilutions are added to the appropriate 
microtiter wells already containing 100 µl of medium, resulting in the required final drug 
concentrations.  
Following drug addition, the plates are incubated for an additional 48 h at 37°C, 5% 
CO2, 95% air, and 100% relative humidity.  For adherent cells, the assay is terminated by the 
addition of cold TCA. Cells are fixed in situ by the gentle addition of 50 µl of cold 50% 
(w/v) TCA (final concentration, 10% TCA) and incubated for 60 minutes at 4°C.  The 
supernatant is discarded, and the plates are washed five times with tap water and air dried.  
Sulforhodamine B (SRB) solution (100 µl) at 0.4 % (w/v) in 1 % acetic acid is added to each 
well, and plates are incubated for 10 minutes at room temperature.  After staining, unbound 
dye is removed by washing five times with 1% acetic acid and the plates are air dried.  
Bound stain is subsequently solubilized with 10 mM trizma base, and the absorbance is read 
on an automated plate reader at a wavelength of 515 nm.  For suspension cells, the 
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methodology is the same except that the assay is terminated by fixing settled cells at the 
bottom of the wells by gently adding 50 µl of 80 % TCA (final concentration, 16 % TCA).  
Using the seven absorbance measurements [time zero, (Tz), control growth, (C), and test 
growth in the presence of drug at the five concentration levels (Ti)], the percentage growth is 
calculated at each of the drug concentrations levels.  Percentage growth inhibition is 
calculated as:  
[(Ti-Tz)/(C-Tz)] x 100 for concentrations for which Ti>/=Tz  
[(Ti-Tz)/Tz] x 100 for concentrations for which Ti<Tz.  
Three dose response parameters are calculated for each experimental agent.  Growth 
inhibition of 50% (GI50) is calculated from [(Ti-Tz)/(C-Tz)] × 100 = 50, which is the drug 
concentration resulting in a 50% reduction in the net protein increase (as measured by SRB 
staining) in control cells during the drug incubation.  The drug concentration resulting in total 
growth inhibition (TGI) is calculated from Ti = Tz.  The LC50 (concentration of drug 
resulting in a 50% reduction in the measured protein at the end of the drug treatment as 
compared to that at the beginning) indicating a net loss of cells following treatment is 
calculated from [(Ti-Tz)/Tz] × 100 = -50.  Values are calculated for each of these three 
parameters if the level of activity is reached; however, if the effect is not reached or is 
exceeded, the value for that parameter is expressed as greater or less than the maximum or 
minimum concentration tested.  
6.4.2 Results and Discussion 
Totally, 22 active compounds were sent to NCI-DTP and all were identified as new 
chemical entities with anticancer activity.  The biological study is still ongoing. 
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6.5 MD ANDERSON CANCER CENTER: 
As a primary assay to examine the effect of the compounds on cell growth, the metabolic 
activity of living cells treated with eight selected compounds (Figure 6.2) was measured by 
the MTT assay (see section 6.5.1).  A panel of pancreatic cancer cells, namely BXPC-3, 
Panc-1, and Capan-2, as well as an immortalized cell line derived from normal pancreatic 
epithelium, E6E7, were tested in the assay.  Among these cell lines, BXPC-3 was the most 
sensitive cell line to most compounds tested, while Capan-2 was the most resistant.  The data 
are summarized in section 6.5.2 and Figures 6.3 – 6.8. 
6.5.1 Methodology of MTT Assay 
The MTT assay20 was used to access the killing effect of the drugs.  Cells were seeded 
into 96 well plates at a density of 6000 cells in 50 µl of media per well.  The drug was 
dissolved in DMSO at a stock concentration of 0.01 M and then diluted in culture media to 
give different drug concentrations for testing in duplicates.  The amount of DMSO was 
equalized for all of the wells and the total volume of media containing the drug was 50µl.  
After 72 hours of incubation at 37 °C in 5% CO2, 25µl of MTT [3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium bromide] reagent was added to each well and incubated for two 
hours.  Then 100 µl of cell lysis buffer was added and incubation was continued overnight.  
The plates were then read on a plate reader at OD 570.  The cell killing efficiency was 
determined by plotting the percent of survival cells with different concentrations of the 
compounds in the same family, which were tested side-by-side.  The MTT reading derived 
from the cells treated by DMSO only was set as 100%. 
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6.5.2 Results and Discussion 
The following observations are of particular interest from the screening results.  WLY-
WP 5COOH displayed better killing in the pancreatic cancer cell line (panc-1) compared 
with the "normal" pancreatic line (E6E7), specifically at 10-20 µM (Figure 6.3).  WLY-
Waisp-OH showed a similar difference between pancreatic cancer and “normal” cells (Figure 
6.4).  These observations will be confirmed by using more pancreatic cancer cell lines and 
fine-tuning the doses used.  WLY-WP5OH had outstanding general cytotoxicity (Figure 6.5), 
which will be useful information for future SAR study of this series.  WLY-WHP-6COOH 
had a stronger cytotoxic effect against MCF-7 cells compared with MCF-10A, "normal" 
breast cells (Figure 6.6).  This observation will also be confirmed later.  
Compounds WLY-Wa4, WLY-WaispOH, WLY-WaLP6OH, and WLY-Wac6OH 
strongly inhibited cell survival and showed similar activity trends against four cell lines, 
E6E7, Panc-1, Capan-2, and CxPC-3 (Figures 6.7 and 6.8).  While most cell lines exhibited 
significant sensitivity to these compounds, the Capan-2 cancer cell line was relatively 
resistant, with WaispOH having the strongest toxicity (Figure 6.8).  However, lack of 
specificity is a major concern as the "normal cell" control E6E7 was quite sensitive to 
compound treatment (Figure 6.7).  It remains possible that E6E7 does not represent the real 
situation in normal pancreas tissue and, therefore, is not the ideal control. 
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Figure 6-2. Structure of WLY-series tested at MD Anderson Cancer Center 
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Figure 6-3. MD Anderson Screening Data – Inhibition of Compound WP6COOH  
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Figure 6-4. MD Anderson Screening Data – Inhibition of Compound WaispOH 
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Figure 6-5. MD Anderson Screening Data – Inhibition of WP5OH 
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Figure 6-6. MD Anderson Screening Data – Inhibition of WHP6COOH 
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Figure 6-7. MD Anderson Screening Data – Inhibition of Compounds WaC6OH, WaispOH, 
Wa4OH and WaLP6OH at 0, 0.5, and 2 µM 
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Figure 6-8. MD Anderson Screening Data – Inhibition of Compounds WaC6OH, WaispOH, 
Wa4OH and WaLP6OH at 0, 0.5, and 2 µM  
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6.6 ANTI-TELOMERASE ASSAY 
Eukaryotic chromosomes end in DNA-protein complexes called telomeres, which 
function as protective caps that prevent nucleolytic degradation, end-to-end fusions, and 
aberrant recombination.  In the absence of properly capped telomeres, cells are not able to 
divide thus either becoming senescent or undergoing apoptosis.  Human telomeric DNA is 
composed of G-rich repeated sequences, (TTAGGG), which are not replicated efficiently by 
the normal DNA replication machinery because of the end-replication problem.21  Instead, 
the G-rich strand of telomeric DNA is maintained by a RNA-dependent DNA polymerase 
called telomerase.  Telomerase is a ribonucleoprotein complex that acts as a reverse 
transcriptase in the maintenance of chromosome ends, therefore preventing cell programmed 
death.22 The minimally active human telomerase complex is composed of hTERT, a catalytic 
protein subunit, and hTR, a RNA subunit, which supply the template for telomeric DNA 
synthesis.23-26 Telomerase activity is usually not present in most normal cells, but it is seen in 
cancerous and some precancerous cells.  The maintenance of telomeric DNA is vital for 
tumor growth, and telomerase-mediated telomere extension is required for the growth of 
>90% of all cancers.27 When telomerase is inhibited in positive cancer cell lines, telomere 
extension is disrupted leading to senescence or apoptosis.  
Telomerase requires the proper association of hTERT and hTR to form an active 
complex.  Dr. M. Jarstfer (UNC-CH) uses a telomerase assemblage assay to test if small 
molecules affect telomerase activity by preventing telomerase assemblage.  Recombinant 
telomerase is assembled in rabbit reticulocyte lysates (RRL), followed by a direct assay for 
telomerase activity that follows extension of a telomeric primer using [α-32P]-dGTP as one of 
the substrates.  
 121  
6.6.1 Methods 
In Vitro Transcription and Purification of hTR.28 A total of 15 µg of phTR+HH was 
linearized by digestion with Fok-1 followed by extraction with phenol/chloroform/isoamyl 
alcohol, precipitation with ethanol, and resuspension in a suitable volume of TE (10 mM 
Tris-HCl, pH 7.5, and 1 mM EDTA).  In vitro transcription was carried out at 37 C for 18 h 
using the linearized DNA, 0.32 units/µL T7 RNA polymerase (Promega), 1× transcription-
optimized buffer (Promega), 10 mM DTT, 0.8 units/µL RNasin (Fisher Scientific), 5 mM 
MgCl2, and 1 mM each NTP.  After transcription, the magnesium-inorganic diphosphate 
complexes were removed by centrifugation for 2 min at 22000g.  Cleavage by the 
hammerhead ribozyme was initiated by the addition of MgCl2 to a final concentration of 12 
mM followed by incubation at 45 C for 1 h.  The entire reaction was then treated with 15 
units of RQ1-DNase (Promega) for 20 min at 37 C followed by extraction with 
phenol/chloroform/isoamyl alcohol and ethanol precipitation.  The RNA was resuspended in 
a suitable volume of denaturing loading buffer (7 M urea/10% glycerol/1× TBE) and purified 
on a 4% denaturing polyacrylamide gel.  The RNA was recovered using a modified version 
of the "crush and soak" method.28 Briefly, the RNA was located in the gel by UV shadowing, 
cut out, crushed by passing through a sterile plastic syringe, and extracted into 2 vol of 1× 
TEN (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 200 mM NaCl) at 4 C for 16 h.  After 
centrifugation, the supernatant was collected and a second extraction was performed with 2 
vol of 1× TEN at room temperature for 1 h.  The combined supernatants were filtered 
through a Whatman GF/C filter, precipitated with ethanol, and resuspended in a suitable 
volume of TE.  
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Synthesis of hTERT.  hTERT was transcribed and translated using the TNT Coupled 
Reticulocyte Lysate Systems kit (Promega).  A 400 L reaction contained 8 µg of pET-28c-
hTERT, and other components provided in the kit as described by the manufacturer.  The 
reaction was incubated at 30 C for 90 min, flash-frozen in a dry ice/ethanol bath, and stored 
at -80 C.  
Telomerase assemblage assay.  Recombinant hTERT was transcribed and translated 
from pET28c-hTERT using the TNT® Coupled Reticulocyte Lysate Systems Kit (Promega) 
following the manufacture’s instructions.  Telomerase assemblage assays were performed by 
first combining 10 µL (~ 50 fmol) of hTERT from reticulocyte lysate reaction, 3.5 µL of 61 
ng/µL of in vitro transcribed hTR, 0.6 µL of DMSO or different inhibitors diluted in DMSO 
and 0.9 µL of water.  The reaction was allowed to incubate for 30 ºC for 90 min.  It was then 
added to the 15 µL reaction, 0.4 µL of different inhibitors or DMSO and 0.6 µL of water, 
followed by 50 mM Tris-HCl, pH 8.0, 50 mM KCl, 1 mM MgCl2, 5 mM β-mercaptoethanol, 
1 mM spermidine, 1 µM human telomere primer (5'-TTAGGGTTAGGGTTAGGG), 0.5 mM 
dATP, 0.5 mM dTTP, 2.9 µM dGTP, 0.33 µM [χ-32P]-dGTP (3000 Ci/mmol, 10 µCi/µL; 
Perkin-Elmer) to reach a total volume of 25 µL.  Inhibition studies were done using 50 µM 
final concentration of different inhibitors.  Primer extension was carried out at 30º C for 90 
min.  After the addition of a 32P-labeled loading control (114 nucleotide, 5'-end labeled 
DNA oligonucleotide, 1000 cpm per reaction), the primer extension products were extracted 
with phenol/chloroform/isoamyl alcohol and ethanol precipitated in the presence of 0.6 M 
NH4OAc and 35 ng /µL glycogen.  Products were precipitated at -80 oC in 2.5 vol of 
absolute ethanol for 30 min followed by centrifugation at 22 000g at 4 oC for 25 min and 
washing with 2 vol of 70% ethanol.  Pellets were resuspended in a suitable volume of TE, 
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and ethanol precipitation was repeated to ensure the removal of all unincorporated [α-32P]-
dGTP.  The final pellets were dissolved in a formamide loading buffer containing 40% 
formamide, 10 mM Tris-HCl, pH 8.0, 10 mM EDTA, 0.05% xylene cyanol, and 0.05% 
bromophenol blue.  The products were heated at 95 C for 5 min and resolved on a 
prewarmed, 0.4 mm thick, 20 × 20 cm, 10% polyacrylamide/7 M urea/1× TBE gel.  The gel 
was run at 800 V for 1 h in 1× TBE.  After drying the gel and exposing it to a 
phosphorimager screen (Molecular Dynamics) overnight, telomerase activity was imaged 
using a phosphorimager (Molecular Dynamics Storm 860) and quantified with ImageQuant 
(version 5.2).  The intensities of each band in each sample were summed and normalized to 
the loading control. 
6.6.2 Results 
We used the above-described telomerase assemblage assay to test if selected PBT 
compounds (40-45, Figure 6-9) could affect direct inhibition of the telomerase enzymatic 
activity.  We used 50 µM of the selected compounds to get the percent activity in the 
telomerase assay as shown in Figure 6-10 and the results are illustrated graphically in Figure 
6-11.  Compounds 42, 43, 44, and 45 showed almost complete inhibition.  Further testing 
should be done using a post-assemblage assay to see if the compounds inhibit the assemblage 
of hTERT and hTR or if they inhibit telomerase by another mechanism. 
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Figure 6-9. Structures of compounds 40-45 screened in telomerase assay 
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Figure 6-10. Telomerase Assemblage Assay 
[Telomerase inhibition was caused by different compounds. The 32P-labeled 
loading control (L.C.) and the human telomere primer extension products (+4, +10, 
+16, +22, etc. nucleotides added) are indicated.] 
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Figure 6-11. Telomerase activity inhibition by compounds 40-45 
 
 
6.7 IN VIVO STUDY  
6.7.1 Objective 
To evaluate possible anticancer activity of 4 PBTs, WLYWaispOH, WLY-Wac6OH, 
WLY-WaLP6OH and WLY-Wa4OH, in Tumor, Xenograft, Lung, A549 Cell in SCID mice 
[580900]. 
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Figure 6-12. Structures of WLY-WaispOH, WLY-WaLP6OH, WLY-Wa4OH and WLY-
WaC6OH used for in vivo screening 
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6.7.2 Methods 
Assay # 580900 Tumor, Xenograft, Lung, A549 Cell 
Severe Combined Immune Deficiency (SCID) male mice were used. Viable human lung 
tumor cells (A549) at a size of 1.5 x 107 cells in 0.2 ml were injected subcutaneously into the 
dorsal side of the test animals.  When the tumor grew and reached ≥ 5 mm in diameter 
(designated as day 1), the tumor-bearing animals were divided into 14 groups (6 animals in 
each group) for antitumor studies. 
For the inhibition of tumor growth, when the A549 tumor grew to reach ≥ 5 mm, WLY-
WaispOH, WLYWac6OH, WLY-WaLP6OH and WLY-Wa4OH at 10, 3 and 1 mg/kg were 
administered at 4-day interval by intraperitoneal injection for a total of 6 doses using the 
dosing volume of 10 ml/kg.  
Mitomycin at 2 mg/kg was given at 4-day interval for a total of 5 doses by IP injection.  
The animals were observed for signs of overt toxicity after dosing.  Body weight and tumor 
size were measured and recorded every 4 days during the experiment period of 29 days. 
Tumor weight (mg) was estimated according to the formula: length × (width)2 × 0.5 in 
mm3, assuming its specific gravity to be 1.  Tumor growth inhibition was calculated as T/C 
(treatment/control) by the following formula: 
T/C = (Tn – T1)/(Cn – C1) x 100% 
If (Tn-T1) < 0, then 
T/C = (Tn - T1)/T1 x 100% 
C1 (Cn): Tumor weight of day 1 (day n) in the control group 
T1 (Tn): Tumor weight of day 1 (day n) in the treated group 
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The result of T/C value ≤ 42% is considered significant antitumor activity. 
6.7.3 Results and Discussion 
In the xenograft model of human lung tumor cells (A549, ATCC CCL-185) in male 
SCID mice, WLY-WaispOH, WLY-Wac6OH, WLY-WaLP6OH and WLY-Wa4OH at 10, 3 
and 1 mg/kg were administered by intraperitoneal (IP) injection at 4-day interval (q4d) for a 
total of 6 doses.  The tumor size, body weight and signs of overt toxicity following test 
compound dosing were monitored and recorded for the duration of the experiment (29 days).  
Tumor growth inhibition was calculated as T/C (treatment/control) × 100%. 
It appears that intraperitoneal administration of WLY-Wac6OH, WLY-WaLP6OH and 
WLY-Wa4OH at 10, 3 and 1 mg/kg q4d for a total of 6 doses did not cause any significant 
inhibition of tumor weight relative to the vehicle control during the experiment period of 29 
days; WLY-WaispOH at 10 mg/kg, however, caused significant tumor inhibition on day 5 
and moderate growth inhibition from day 9 to day 29 (the tumor growth data in terms of 
percent tumor weight relative to the vehicle control group are shown Figure 6-13). 
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Figure 6-13. The tumor growth curves in SCID mice treated with WLY-WaispOH 
 
 
Body weight and overt toxicity were monitored during the study.  In comparison with 
the vehicle-treated control group, WLY-WaispOH, WLY-Wac6OH, WLY-WaLP6OH and 
WLY-Wa4OH at 10, 3 and 1 mg/kg were not associated with any changes in body weight 
and overt toxicity (Figure 6-14). 
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 Figure 6-14. The body weight curves in SCID mice treated with  
WLY-WaispOH, WLY-Wac6OH, WLY-WaLP6OH and WLY-Wa4OH
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7 CHAPTER VII.  CONCLUSIONS AND FUTURE STUDIES 
 
 
7.1 STRUCTURE ACTIVITY RELATIONSHIP  
In this study, we have designed and synthesized new water-soluble phenanthrene-based 
tylophorine derivatives (PBTs) as potential antitumor agents.  These compounds contain a 
core phenanthrene structure and can be synthesized efficiently in excellent yield.  To obtain 
structure-activity relationship (SAR) information, we carried out chemical modification on 
nine different positions of the compound skeleton (Figure 7-1).  
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Figure 7-1. SAR Study of PBTs 
 
 
A total of more than 70 PBTs were synthesized and evaluated for cytotoxic activity 
against the A549 human cancer cell line.  Among them, N-(2,3-methylenedioxy-6-methoxy-
phenanthr-9-ylmethyl)-L-4-piperidinemethanol (1), N-(2,3-methylenedioxy-6-methoxy-
 
phenanthr-9-ylmethyl)-L-2-piperidinemethanol (2), N-(2,3-methylenedioxy-6-methoxy-
phenanthr-9-ylmethyl)-4-piperidineethanol (3) and N-(2,3-methylenedioxy-6-methoxy-
phenanthr-9-ylmethyl)-6-aminohexanol (4) (Figure 7-2) showed the highest potency with 
EC50 values of 0.08, 0.16, 0.15 and 0.2 µM, respectively, which are comparable to those of 
currently used antitumor drugs.   
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Figure 7-2. Structures of promising PBTs developed in the NPL 
 
 
These four compounds incorporated all of the favorable modifications identified to date 
in the preliminary SAR study.  The favorable modifications for these novel PBTs are as 
follows (Table 7-1).  1) A planar phenanthrene system is required, but not sufficient for 
cytotoxic activity.  2) An N-hydrophilic substituent at the C-9 position is essential for 
enhanced cytotoxicity and should be linked through a methylene rather than a carbonyl group.  
3) This C-9 N-hydrophilic substituent is ideal for the introduction of a polar moiety.  Analogs 
containing terminal carboxylic acid or hydroxymethyl groups are more favorable than those 
with methyl esters.  4) On the phenanthrene skeleton, a methoxy substituent best fits both the 
steric and electronic requirements at the C-6 position and is preferred over benzyloxy and 
hydroxy groups.  5) Adding a methylenedioxy ring at the 2, 3 position of the planar 
phenanthrene system can dramatically enhance the cytotoxic activity and led to the most 
potent derivatives. 
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Table 7-1. SAR of PBTs. 
 
7.1.1 Position Number 7.1.2 SAR Result 
1. Phenanthrene Skeleton 
A planar phenanthrene system is required, but not 
sufficient for cytotoxic activity. 
2. C-2, C-3 Substituent 
Adding a methylenedioxy ring at the 2,3 position of 
the planar phenanthrene system enhanced the 
cytotoxic activity and led to the most potent 
derivatives.  
3. C-6 Substituent 
A methoxy substituent best fits both the steric and 
electronic requirements at the C-6 position and is 
preferred over benzyloxy and hydroxy groups. 
4. C-9 Linkage 
An N-hydrophilic substituent at the C-9 position is 
essential for the enhanced cytotoxicity and should be 
linked through a methylene rather than a carbonyl 
group.   
5. C-9 Terminal Substitutent 
C-9 N-hydrophilic substituent is ideal for the 
introduction of a polar moiety.  Analogs containing 
terminal carboxylic acid or hydroxymethyl groups are 
more favorable than those with methyl esters. 
6. Length of C-9 Side Chain 
The distance between the nitrogen and terminal 
substituent affected the potency; 6 carbon length is 
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the most favorable for the activity. 
7. Stereochemistry of the 2’-
Substituent 
2’S–substituted compounds showed equal or higher 
cytotoxicity than R isomers. 
8. C-9 Side Chain Orientation 
The terminal hydroxyl/carboxylic acid in a para 
position could favorably affect the activity compared 
with other orientations. 
9. Nitrogen Content 
The second nitrogen was tolerated; its presence 
slightly decreased activity. 
 
In summary, the new PBT derivatives possess a novel structure and showed remarkable 
EC50 values in the sub-micromolar range, comparable with current front-line antineoplastic 
drugs such as etoposide.  These derivatives are the first reported water soluble tylophorine 
derivatives with remarkable cytotoxic activity, in particular against multidrug-resistant 
cancer cell lines, suggesting a great potential of developing this compound class into 
antitumor agents to treat cancer (particularly for refractory cancer). 
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7.2 FUTURE STUDIES 
7.2.1 Short total synthesis of phenanthroindolizidine alkaloids. 
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Scheme 7-1. Short total synthesis of antofine 
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Scheme 7-2. Base-induced cyclization 
 
 
Russel and Hunziker proposed a base-promoted ring closure in the total synthesis of 
septicine.1 Using this methodology in step d of Scheme 7-1 allows a modified total synthesis 
of the phenanthroindolizidine ring.  The target compound will be accessed in five steps, 
which should be the shortest synthetic route reported to date.  This synthetic route avoids an 
unstable ketone intermediate by using an intramolecular based-induced cyclization of amino 
alcohols.  In addition to the base-induced cyclization, a Lewis acid mediated Friedel-Crafts 
type cyclization was also reported (Scheme 7-2).2 Several bases or Lewis acid will be 
examined for this step. 
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7.2.2 Parallel Synthesis of PBTs 
A general method of rapidly preparing PBT analogs would be advantageous and merits 
investigation for drug discovery.  Meanwhile, parallel synthesis of small organic molecules 
has emerged as an important technology, enabling chemists to synthesize numerous 
pharmaceutically interesting compounds.3  The relative ease of automation, along with a 
multiple parallel synthesis strategy, has greatly supported the growing needs for identifying 
novel biologically active lead compounds and accelerated structure-activity relationship 
studies in drug discovery. 
We will apply parallel synthesis of new PBTs using an active ester resin4 procedure.  
The synthetic route is described in Scheme 7-3. 
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Scheme 7-3. Parallel synthesis of PBTs 
 
General Procedure 
Formation of active ester: 
1.5 equiv of carboxylic acid, 4.5 equiv of DIC, 0.6 equiv of DMAP, and a 4:1 
DCM/DMF solvent mixture at room temperature for 2–3 h.  Order of addition proved to be 
an important variable: DMAP and the carboxylic acid were mixed with PS-HOBt(HL), 
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followed by addition of DIC.  The purpose of including DMF as a cosolvent is to improve the 
solubility of the carboxylic acid component.  It is preferable to keep the DMF composition in 
the reaction mixture to a minimum (< 20%), since it compromises the level of active ester 
formation.  If more DMF is required to dissolve the carboxylic acid, up to 50% DMF can be 
used; however, the loading level will be reduced.  
 
Amide synthesis 
To 1.5 equiv of PS-HOBt(HL) active ester resin was added a mixture of 0.7 equiv of 
amine and 1.0 equiv of DIEA in DCM or THF and the mixture was stirred at 25 °C for 3 h. 
The solution was filtered, and the resin rinsed with DCM or THF (3 ×).  The combined 
filtrate was concentrated to afford the desired amide. 
7.2.3 Making Organic/inorganic Salt 
In the multi-cancer cell assay study, the corresponding HCl salt of the active free base 
showed better water solubility, while still retaining similar cytotoxic activity.  Making 
organic/inorganic salt is a very useful way to improve a compound’s pharmacological 
properties.  Thus, we continue to prepare the pharmaceutically acceptable salts of active 
compounds.  Pharmaceutically acceptable salts are salts that retain the desired biological 
activity of the parent compound and do not impart undesired toxicological effects.  Examples 
of such salts are (a) acid addition salts formed with inorganic acids, such as hydrochloric acid, 
hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed 
with organic acids, such as acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, 
fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, 
palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic 
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acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; 
and (b) salts formed from elemental anions such as chlorine, bromine, and iodine. 
7.2.4 Design of Bioisosteric Skeleton Modification 
Bioisosteric modification may profoundly affect pharmacological action, metabolism 
activity, and toxicity.  This basic principle of analog design has been successfully applied in 
many natural product modifications.  Therefore, we will apply this approach in new PBTs 
development.  The general molecular formulas of new PBTs are shown in Figure 7-3 and 
these compounds should be efficiently synthesized by our general procedure in chapter III or 
parallel synthesis mentioned in section 7.2.2.  
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Figure 7-3. Structure Formulas of New PBTs 
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7.2.5 Mechanism of Action Study 
The biological target of PBTs is still unknown and the mechanism of action of PBTs has 
not been elucidated.  The preliminary results have shown that PBTs are a unique class of 
antitumor compounds that may have a mode of action different from known antitumor drugs.  
The active PBTs will be screened against several interesting cancer-related targets, such as 
NFҝB, topoisomerase, etc.  It would be helpful to assign a putative mechanism of action and 
identify a specific molecular target with which PBTs are most likely to interact.  More cancer 
cell lines will be used to characterize selective growth inhibition or cell killing of particular 
tumor cell lines.  The further screening of PBTs will facilitate the understanding of SAR and 
provide more rationale to design a more potent compound targeting wild/resistant cancer 
cells. 
7.2.6 QSAR study and Database Mining 
The approach applied herein to QSAR modeling of PBTs does not stop since more new 
PBTs will come into the database and more pharmacological datasets will be available for 
screening.  Our approach places the emphasis of the entire QSAR modeling study on making 
reliable predictions of chemical structures expected to have the desired biological activity, 
rather than on respectable statistical characteristics of (training set) models.  These predicted 
structures either are already available in existing chemical databases or are synthetically 
feasible (i.e., included in virtual combinatorial chemical libraries, which can also be mined 
with QSAR models).  The focus of the modeling will be brought closer to the needs of 
medicinal chemists who both supply computational chemists with experimental structure-
activity data and expect novel structures rather than equations and statistical parameters in 
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return.  We believe that this approach will bring QSAR modeling in tune with the ultimate 
needs of our interest in new plant-derived anti tumor agents. 
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